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ABSTRACT 
 
ESTABLISHMENT AND REGULATION OF EPITHELIAL ENHANCERS BY P63 
Enrique Lin Shiao 
Shelley L. Berger 
 
The transcription factor p63 is a key mediator of epidermal commitment, development, and 
differentiation. Point mutations in p63 in human patients lead to developmental defects, including 
orofacial clefting, one of the most common congenital defects in humans. To date, knowledge is 
limited about how pivotal is p63’s role in human craniofacial development, due in part to a lack of 
tractable models to study de novo expression of p63 and its role at developmentally regulated 
genes. Using an inducible trans-differentiation model, combined with epigenomic sequencing and 
multi-cohort meta-analysis of GWAS data, we show that p63 establishes enhancers at 
craniofacial development genes to modulate their transcription. We further identify histone 
methyltransferase KMT2D as a key interacting partner of p63 at these enhancers and identify a 
novel role for this histone methyltransferase in maintaining epithelial homeostasis. Our results 
demonstrate that disease-specific substitution mutation in the DNA binding domain or SAM 
protein interaction domain of p63 respectively eliminate or reduce establishment of these 
enhancers.  Finally, we show enhancers established by p63 are highly enriched for SNPs 
associated with nonsyndromic cleft lip +/- cleft palate (CL/P). These orthogonal approaches 
indicate a strong molecular link between p63 enhancer function and CL/P, illuminating molecular 
mechanisms underlying this developmental defect and revealing vital regulatory elements and 
new candidate causative genes. 
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1 
 
CHAPTER 1: Introduction 
 
1.1: Epigenetics 
One of the most fascinating hallmarks in biology is how multicellular organisms can form 
from a single cell and how cells with an identical genome can show so many different 
phenotypes. The main difference between distinct cells in an organism comes down to what 
genes are expressed in each cell and this is in part modulated by the organization of DNA into 
chromatin. In chromatin, DNA wraps around proteins known as histones that function as spools to 
allow DNA to be organized in a particular way within the nucleus. Both DNA and histones can be 
covalently modified to modulate the organization of DNA in the nucleus and ultimately regulate 
gene expression (Figure 1.1). The study of heritable changes in gene expression patterns that do 
not involve modifications in the DNA sequence is known as epigenetics1,2. Epi- comes from the 
Greek and means over, outer or above. 
              
Figure 1.1: Chromatin can be covalently modified to modulate its organization in the 
nucleus. Figure adapted from Weaver et al.3  
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Many epigenetic mechanisms have been identified thus far, including the role of DNA 
methylation, histone modifications and long non-coding RNAs in modulating gene expression1–4. 
However, how all these different mechanisms act in concert to regulate complex processes, such 
as lineage specification and development, remains to be elucidated. Additionally, how disruption 
of these mechanisms can lead to disease is largely unclear. The completion of the human 
genome project and the advancement of next generation sequencing technologies have opened 
up a plethora of new avenues to study epigenetics and start to answer some of these questions. 
 
1.2: From enhancers to lineage specification 
In 1972 the geneticist Susumu Ohno coined the term “junk DNA” to refer to parts of the 
genome that did not encode for proteins and which many people believed had no function5. The 
completion of the human genome project in 2003 showed that only about 1% of the human 
genome are protein-coding regions, encompassing about 21.000 protein-coding genes6,7. 
However, a great amount of evidence has accumulated since then to demonstrate that many 
parts of the non-coding genome perform important regulatory functions to modulate gene 
expression4,8–10.  
Cis-regulatory elements, in particular, are regions of non-coding DNA that regulate 
transcription of neighboring genes8. The best characterized cis-regulatory elements include 
promoters and enhancers, both of which can be bound by transcription factors to modulate 
downstream gene expression. Promoters are primarily localized ~50 base pairs(bp) upstream or 
downstream of the transcription start site (TSS), while enhancers can be localized upstream, 
downstream, within intronic regions or even mega bases apart from the genes they regulate11,12. 
While promoters are sufficient to assemble RNA Pol II machinery to start transcription, 
transcription is often low in the absence of enhancers11,13. 
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The first enhancer was identified about 40 years ago, as part of the sequence of the 
SV40 virus genome14,15. Isolation and introduction into a reporter in HeLa cells demonstrated over 
100-fold enhancement of transcription of a reporter gene14. Since then, many enhancers have 
been identified in mammalian genomes and their biochemical and functional properties have 
been thoroughly investigated10,12,13. Comparative genomics facilitated the identification of 
enhancers by looking at highly conserved non-coding regions across vertebrates and 
mammals16–18. With the advent of next-generation sequencing, many more enhancers have been 
described in the past decade and key features have been found to de novo identify enhancers: 
open chromatin, decorated by histone modifications (H3K27ac, H3K4me1, H3K122ac and 
H4K16ac), bound by RNA Pol II and transcription factors; and expression of enhancer RNAs 
(eRNAs)19–26. (Figure 1.2)
                                   
Figure 1.2: Anatomy of enhancers. Specific chromatin features have been found to be 
characteristic to enhancers, including activating histone modification marks, depletion of 
nucleosomes, active transcription and binding of transcription factors. 
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 Enhancers and promoters are associated to cell fate determination, as they can be bound 
by lineage specific transcription factors and remodeled to regulate tissue specific transcription. 
The current model for how enhancers work posits that active enhancers bound by transcription 
factors can loop towards the promoter through protein-protein interactions at both sites to activate 
downstream transcription of specific genes27–31 (Figure 1.3). Many questions remain around 
enhancers, particularly how enhancers are established, maintained and inherited through cell 
divisions is not fully understood12. 
 
Figure 1.3: Enhancers are non-coding regions of DNA that regulate cell-type specific gene 
expression and maintain cell identity. Local expression of a gene during brain and limb 
development is achieved by binding of tissue specific transcription factors to distinct upstream 
enhancers and looping of the enhancer to the promoter region. Figure adapted from Visel et al.27 
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Hematopoiesis is perhaps one of the best studied models for lineage commitment and 
the β-globin locus involved in erythroid differentiation is among the first and most thoroughly 
characterized gene clusters at which long-range interactions between a distal enhancer and 
target β-globin promoters have been observed29,32,33.During hematopoiesis, hematopoietic stem 
cells (HSC) undergo transcriptional and epigenetic changes associated with lineage restriction 
and cell specification to give rise to all the hematopoietic cell types34–36. Key transcription factors, 
such as GATA1 and GATA2 have been identified in this process that modify chromatin structure 
and gene expression to regulate cell fate decisions.  Translocations in the the β-globin locus have 
been shown to result in thalassaemias even when substitution mutations have not been found in 
the the β-globin genes, showing that diseases can emerge as a consequence of disruption of 
enhancer function37. 
Genetic variation in distant enhancers has been linked to many more human Mendelian 
disorders, including pre-axial polydactyly due to mutations in an enhancer controlling sonic 
hedgehog (SHH)38, Holt-Oram syndrome (exhibiting cardiac and limb malformations) due to 
mutations in an enhancer controlling TBX539 and many other disorders40–42. Importantly genome-
wide association studies (GWAS) have shown that the majority of disease-associated variants 
are not localized within protein-coding regions but instead are localized at non-coding regions and 
many could possibly be localized at enhancers43,44.  
In order to understand how enhancers may influence different diseases, it is necessary to 
expand our knowledge about how enhancers are specified in different lineages and fates beyond 
the hematopoietic pathway and how mutations in enhancer regions can lead to dysregulation of 
gene expression in different cell types. 
 
1.3: The epidermis 
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The surface epithelium of the skin or epidermis forms the outermost layer of cells in the 
body, providing a direct physical, chemical and immunological barrier between the body and the 
environment. The epidermis is self-renewing, with progenitor basal keratinocytes giving rise to all 
the differentiated layers of the stratified epidermis45(Figure 1.4). This differentiation process 
occurs through an outward migration and terminal differentiation program that is tightly controlled 
by epigenetic changes and by spatiotemporal expression of epithelial specific genes.  
                                                     
Figure 1.4: The epidermis is composed of stratified layers that stem from the progenitor 
basal keratinocytes. Schematic of an epidermis section showing the different layers. Figure 
taken from Anatomy of the Human Body46. 
 
Dysfunction of epidermal lineage specification and differentiation is associated with over 
a hundred human genetic diseases, impacting over 20% of the population47. Some of the most 
severe diseases include epidermolysis bullosa (manifested by skin blistering and erosions), 
squamous cell carcinomas, as well as ectodermal defects (showing orofacial clefting and limb 
malformations)47. Given the high incidence of epidermal disorders in humans it is imperative to 
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understand the molecular mechanisms that lead to epithelial specification and differentiation and 
study how these processes are affected in disease. 
The mammalian epidermis derives from the ectoderm through a process of lineage and 
cell fate specification that results in the stratified squamous epithelium48. The consequent 
differentiation of basal epidermal cells into terminally differentiated cells of the cornified layer has 
been thoroughly studied and characterized45,49. However, the early events that lead to the 
commitment of epidermal stem cells and progenitor cell populations are still not completely  
understood. 
Bone morphogenetic protein (BMP) and retinoic acid (RA)50–52 initially specify the 
epidermal lineage from the lateral surface ectoderm. The surface ectoderm is a single-layered 
epithelium characterized by the expression of markers keratin 8(KRT8) and keratin 18(KRT18).  
In the presence of epidermal growth factor, fibroblast growth factor and insulin, the surface 
ectoderm commits to form the stratified epidermal progenitors known as basal membrane 
keratinocytes which express keratin 5(KRT5) and keratin 14(KRT14)52,53. The basal keratinocytes 
can then further differentiate to produce stratified multi-layered skin. 
Mouse developmental models, human syndromes and in vitro epidermal differentiation of 
pluripotent stem cells (PSCs) have begun to uncover key transcription factors required for 
epidermal lineage specification and differentiation. A key transcription factor involved in regulating 
gene expression programs to modulate these processes is p63, which has been termed a master 
regulator of epidermal development54,55. 
 
1.4: Transcription factor p63 
Transcription factor p63, a member of the p53 family of proteins, is almost exclusively 
expressed in epithelial cells55. Unlike p53, numerous N- and C-terminal variants of p63 can be 
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transcribed to yield polypeptides that exhibit different functions in transcriptional control, with 
ΔNp63α as the most abundant and best characterized isoform in epithelial cells (Figure 1.5)55,56. 
Importantly, the high sequence identity between the DNA binding domains (DBD) of p53 and p63 
allow them to bind to the same DNA consensus motif.  
      
Figure 1.5: p63 can be transcribed as 6 isoforms. Including ∆N and TA (transcriptional 
activation domain) isoforms. Disease related mutations in the DBD and SAM domain of p63 
are highlighted, as well as the high sequence identity with p53.  
 
While deletion of Trp53 (encoding the p53 protein) shows no phenotype at birth57, 
deletion of Trp63 (encoding the p63 protein) in mice leads to clear developmental and 
morphological defects in the squamous epithelia and epidermis, leading to abnormal craniofacial 
development, truncated limbs and loss of salivary glands, hair follicles and teeth54,55 (Figure 1.6). 
In humans, germline missense mutations in p63 cause ectodermal dysplastic syndromes, leading 
to cleft lip/palate and limb malformations47,58,59. Interestingly, these mutations are largely 
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clustered in either the DBD or the sterile alpha motif (SAM) domain and show clear differences in 
the location and severity of phenotypes60. These genetic data strongly implicate p63 in critical 
epithelial cell processes, including establishment of epithelial identity.  
Although p63 mutations have not directly been linked to tumorigenesis61,62, loss of p63 
has been observed in the epithelial to mesenchymal transition (EMT) in several types of cancers, 
including human breast and human prostate adenocarcinoma63,64. Our laboratory previously 
demonstrated that p53 family member proteins, including p63, can directly bind to nucleosome-
occluded DNA sequences, displaying properties more commonly observed in pioneer factors65. 
Pioneer factors are transcription factors that can bind to condensed chromatin and recruit 
chromatin modifiers and other transcription factors to regulate the chromatin landscape and 
enhancer activity66–69. They are critical for specifying cell lineages, presumably through their 
ability to regulate cell type-specific enhancer networks67. While the importance of p63 in the 
development and differentiation of epithelial tissues has been demonstrated in mouse knockout 
models and human syndromes, the biochemical role of p63 in de novo epithelial lineage 
commitment and the molecular and epigenetic mechanisms by which it maintains epithelial cell 
identity though enhancer regulation and pioneer factor activity remain to be elucidated. A main 
reason for this is the difficulty of studying these processes during embryonic development and a 
lack of tractable models to do this70.  
 
1.4: p63 remodels chromatin during epidermal development 
 While the importance of p63 in regulating epidermal development has been known for 
almost 30 years now54,55, the molecular mechanisms by which it achieves this have only recently 
begun to be elucidated. Early on, it was recognized that p63 could bind upstream of genes to 
either activate or repress their transcription55,71. This mechanism was shown to be crucial for 
proliferation and differentiation of human epidermal keratinocytes72–74, regulation of signaling 
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pathways involved in ectodermal organogenesis75 as well as maintenance of proliferative 
potential of epidermal progenitor stem cells76 and more recently regulation of nuclear shape and 
expression of nuclear envelope-associated genes77. 
 A more complete picture of how p63 engages with chromatin to regulate epidermal 
development emerged with the advent of genome-wide high throughput sequencing techniques to 
profile changes in chromatin, including chromatin-immunoprecipitation sequencing (ChIP-Seq)78 
to profile changes in histone modification profiles and binding profiles of transcription factors, as 
well as assay for transposase-accessible chromatin sequencing (ATAC-Seq)79 to profile open and 
closed chromatin regions. Initial experiments demonstrated that p63 binds to over 7000 sites in 
the genome in human foreskin keratinocytes, primarily in intronic regions and upstream of 
promoters80. Furthermore, results demonstrated that p63 bound sites were enriched for H3K4 
monomethylation, a histone modification characteristic of enhancers80. Integrative analysis 
suggested that genes closest to p63 bound sites were downregulated when p63 was knocked 
down81, correlating genome-wide binding of p63 to transcriptional changes and identifying a 
plethora of new genes regulated by p63.   
Other transcription factors and chromatin modifying proteins involved in co-regulation of 
epidermal development with p63 were also identified through genome-wide and biochemical 
experiments, including chromatin reorganizer SATB182, chromatin remodeler BRG183 and 
transcription factor TFAP2C80. Further experiments showed correlation between p63 binding and 
acetylation of histone tail H3 lysine 27 (H3K27ac) during keratinocyte proliferation and 
differentiation suggesting a key role for p63 in regulating epidermal specific enhancers84. A further 
study demonstrated cooperation between the BAF chromatin remodeling complex and p63 and 
showed that both are required in an invitro human epidermal differentiation assay to maintain 
open chromatin regions characteristic of keratinocytes85. 
More recently, experiments using an in vitro epidermal differentiation assay from PSCs 
suggested TFAP2C, but not p63, is sufficient to initiate surface ectoderm differentiation52. These 
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data did show, however, that p63 is necessary for maturation of this differentiation program to 
specify the epidermal lineage. Data from the same group showed p63 could specify different 
transcriptional programs depending on which morphogens it is exposed to51. Another recent 
single-cell study showed p63 is able to remodel open chromatin regions to specify the epidermal 
lineage independently of previously described co-regulatory transcription factors86 and 
unpublished work from the Zhou lab suggests a novel interaction between p63 and CTCF to 
modulate chromatin architecture in skin keratinocytes87. Together the data thus far points towards 
a key role for p63 in regulating epidermal lineage specification, however, many questions remain 
around the mechanism and how p63 engages other transcription factors during this process. 
An additional fundamental question is whether dysregulation of p63’s interaction with 
chromatin plays a role in disease. As mentioned above, substitution mutations in p63 lead to 
ectodermal dysplastic syndromes, including orofacial clefting and limb malformation54,58,88. 
Furthermore, p63 is amplified in a subset of squamous cell carcinomas89–91. Nevertheless, the 
molecular mechanisms behind these disorders are only recently being elucidated. A study 
published last year demonstrated that enhancer reprogramming via p63 in the squamous subtype 
of pancreatic ductal adenocarcinoma promoted migration, invasion and tumor growth92. Another 
study showed that keratinocytes from patients with electrodactyl, ectodermal dysplasia, and cleft 
lip/palate syndrome (EEC), exhibit a clear downregulation of epidermal genes and loss of 
epidermal enhancers93. Finally, murine studies and human genome wide association studies 
(GWAS) have suggested a connection between p63 and clefting of the lip and the palate80,94–96; a 
molecular link however remains to be demonstrated. 
 
1.5: Cleft lip/palate 
Mutations in p63 in humans are rare, however, orofacial clefting [with its distinct subtypes 
cleft lip +/- cleft palate (CL/P) and cleft palate only (CPO)] is a key feature of mutant p63 
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syndromes, and is one of the most common congenital defects world-wide with an approximate 
prevalence of 1:700 births97. The etiology of orofacial clefting is complex, with involvement of 
genetic and environmental factors. To date, over 400 different human syndromes have been 
reported showing orofacial clefting as part of their phenotypic spectrum. However, more than 70% 
of CL/P cases and more than 50% of CPO cases are non-syndromic (ns), presenting as isolated 
phenotypes with absence of other organs and systems affected, and hence their etiology remains 
largely unclear97–100.  The commonality and complexity of the constellation of orofacial clefting 
syndromes suggests involvement of p63-linked regulatory dysfunction.   
Murine models have been crucial in understanding lip and palate development. 
Nonetheless, mutations and knockout of proteins involved in human CL/P in mice rarely show 
clefting of the lip, with clefting primarily observed in the secondary palate101,102. Genome-wide 
association studies (GWAS) and other genetic approaches in human nsCL/P patients have 
identified 40 risk loci that show robust associations of single nucleotide polymorphisms (SNPs) 
with nsCL/P100,103–105. A provocative finding is that the majority of SNPs associated to nsCL/P are 
not found within protein-coding exons but rather at intronic and intergenic regions, and, for the 
vast majority of these SNPs, the molecular mechanism underlying nsCL/P pathogenesis remains 
unknown. A single case in a family with CL/P has been reported in which a substitution mutation 
in p63 disrupts its binding to an enhancer and affects transcription of IRF695. Whether CL/P 
associated SNPs function in a similar way is unknown, and most broadly, how general is 
enhancer disruption in developmental diseases, remains to be elucidated. 
 
In the following chapters I will discuss two studies in which we investigated the role of 
p63 in human craniofacial development (Figure 1.6), and in the pathogenesis of orofacial clefting. 
In the first study,  we developed an inducible trans-differentiation model that reveals p63 
interaction with chromatin when expressed de novo and p63 regulation of gene expression. Our 
strategy encompassed a combination of epigenomic assays, including ATAC-seq, ChIP-seq of 
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p63 and the active enhancer histone modification H3K27ac, along with analysis of nsCL/P GWAS 
data. In parallel, for our second study, we combined mass spectrometry and genome-wide 
approaches to identify novel interactors of p63 at enhancers and characterized their function. Our 
results reveal p63 establishment of enhancers, displaying increased chromatin accessibility and 
de novo H3K27 acetylation, at critical craniofacial genes and demonstrate that substitution 
mutations in p63 abrogate this function. We identify KMT2D as a novel partner of p63 at epithelial 
enhancers and determine a novel role of this histone methyltransferase in coordinating epithelial 
homeostasis and differentiation. Further, we validate known genes and identify novel candidate 
genes and the enhancers that regulate them via p63, that might play a role in nsCL/P 
pathogenesis. Lastly, we show enhancers established by p63 are highly enriched for SNPs 
associated with nsCL/P, providing novel mechanistic insights into regulation of pathogenesis by 
CL/P-associated SNPs. 
  
Figure 1.6: Central Hypotheses. While the importance of p63 in regulating epidermal 
development has been thoroughly studied, the molecular mechanisms by which it achieves this 
are not completely understood. Through investigation of p63’s first encounter with chromatin I aim 
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to understand its role in epithelial enhancer establishment and how this process might be affected 
in cleft lip/palate pathogenesis. 
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CHAPTER 2: p63 establishes epithelial enhancers at critical craniofacial development 
genes  
 
2.1: Introduction 
The transcription factor p63, a member of the p53 family of proteins, is a key mediator of 
epithelial cell processes, including establishment and maintenance of epithelial identity1. Deletion 
of Trp63 (encoding the p63 protein) in mice leads to developmental and morphological defects in 
the squamous epithelia and epidermis, leading to abnormal craniofacial development, truncated 
limbs, and loss of salivary glands, hair follicles and teeth2,3. In humans, germline missense 
mutations in p63 cause ectodermal dysplastic syndromes, which are characterized by orofacial 
clefting and limb malformations4–6. Interestingly, these mutations are largely clustered in either 
the DNA Binding Domain (DBD) or the protein-protein interaction Sterile Alpha Motif (SAM) 
domain; amino acid substitutions show clear differences in the physical location and severity of 
phenotypes7. p63 can bind directly to chromatin to change the chromatin landscape during 
keratinocyte differentiation8–10. However, the role of p63 in de novo epithelial lineage commitment 
and how p63 amino acid mutations lead to defects in this process, remain unknown. 
Mutations in p63 in humans are rare, however, orofacial clefting [with its distinct subtypes 
cleft lip +/- cleft palate (CL/P) and cleft palate only (CPO)] is a key feature of mutant p63 
syndromes, and is one of the most common congenital defects world-wide with an approximate 
prevalence of 1:700 births11. The etiology of orofacial clefting is complex, with involvement of 
genetic and environmental factors. To date, over 400 different human syndromes have been 
reported showing orofacial clefting as part of their phenotypic spectrum. However, more than 70% 
of CL/P cases and more than 50% of CPO cases are non-syndromic (ns), presenting as isolated 
phenotypes with absence of other organs and systems affected, and hence their etiology remains 
largely unclear11–14.  The commonality and complexity of the constellation of orofacial clefting 
syndromes suggests involvement of p63-linked regulatory dysfunction.   
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Murine models have been crucial in understanding lip and palate development. 
Nonetheless, mutations and knockout of proteins involved in human CL/P in mice rarely show 
clefting of the lip, with clefting primarily observed in the secondary palate15,16. Genome-wide 
association studies (GWAS) and other genetic approaches in human nsCL/P patients have 
identified 40 risk loci that show robust associations of single nucleotide polymorphisms (SNPs) 
with nsCL/P14,17–20. A provocative finding is that the majority of SNPs associated to nsCL/P are 
not found within protein-coding exons but rather at intronic and intergenic regions, and, for the 
vast majority of these SNPs, the molecular mechanism underlying nsCL/P pathogenesis remains 
unknown. A single case in a family with CL/P has been reported in which a substitution mutation 
in p63 disrupts its binding to an enhancer and affects transcription of IRF6 21. Whether CL/P 
associated SNPs function in a similar way is unknown, and most broadly, how general is 
enhancer disruption in developmental diseases, remains to be elucidated. 
In this study we investigated the role of p63 in human craniofacial development, and in 
the pathogenesis of orofacial clefting. We used an inducible trans-differentiation model that 
reveals p63 interaction with chromatin when expressed de novo and p63 regulation of gene 
expression. Our strategy encompassed a combination of epigenomic assays, including ATAC-
seq, ChIP-seq of p63 and the active enhancer histone modification H3K27ac, along with analysis 
of nsCL/P GWAS data. Our results reveal p63 establishment of enhancers, displaying increased 
chromatin accessibility and de novo H3K27 acetylation, at critical craniofacial genes and 
demonstrate that substitution mutations in p63 abrogate this function. We validate known genes 
and identify novel candidate genes and the enhancers that regulate them via p63, that might play 
a role in nsCL/P pathogenesis. Lastly, we show enhancers established by p63 are highly 
enriched for SNPs associated with nsCL/P, providing novel mechanistic insights into regulation of 
pathogenesis by CL/P-associated SNPs. 
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2.2: Results 
2.2.1: p63 remodels chromatin to establish enhancers, upregulating epithelial and 
inflammation genes 
To determine whether p63 has the ability to remodel the chromatin landscape to establish 
epithelial enhancers, we set up a doxycycline-inducible system to express the ∆NP63α isoform 
(hereafter referred to as p63) in human BJ dermal fibroblasts (ATCC CRL-2522). After 48 hours, 
p63 reaches an expression level comparable to endogenous levels observed in undifferentiated 
normal human epidermal keratinocytes, and expression levels are maintained without increase at 
72 hours (Supplemental Figure 2.1 a). This p63 isoform was selected because it is the most 
abundant isoform in epithelial cells, is not expressed in fibroblasts, and has been demonstrated to 
play a fundamental role as a regulator of epithelial fate and keratinocyte differentiation22–24.  
Expression of p63 was induced for 72 hours, followed by p63 chromatin precipitation 
(ChIP-seq to assess p63 binding genome-wide), ATAC-seq (to assess open chromatin), and 
H3K27 acetylation (H3K27ac) ChIP-seq (Fig 2.1a). We observed an increase in ATAC-seq 
chromatin accessibility and H3K27 acetylation (H3K27ac) at p63-bound sites in fibroblasts 
expressing p63 compared to control fibroblasts with empty vector (Fig 2.1b, Supplemental Fig. 
2.1b). 40K sites were bound by p63, of which 40% were previously closed chromatin sites 
becoming open only after ectopic expression of p63 (Fig 2.1c, Supplemental Fig. 2.1b; 
17156/27441 peaks), while a smaller proportion were unchanged or closed after p63 expression 
(14991 open before and after; 10302 closed). Further, 40% of these p63 bound sites were 
flanked by H3K27ac with approximately 60% of these sites  showing de novo H3K27ac (Fig 2.1d, 
Supplemental Fig. 2.1b; 12071/20190). Partitioning of p63 bound sites by distance to transcription 
start sites (TSS) revealed that the majority of p63 sites are located at intergenic and intronic 
regions at a median distance of 27kb (Figs 2.1e,f), a distribution that is characteristic of 
enhancers. Overlaying published micrococcal nuclease (MNase) datasets in human fibroblasts25 
with our p63 ChIP sites revealed that 55% of sites bound by p63 when ectopically expressed are 
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nucleosome-occupied in fibroblasts, and 75% of these become open and devoid of nucleosomes 
upon ectopic expression of p63 (Supplemental Fig. 2.1c), expanding on previous work that 
showed p63 has the ability to bind to closed chromatin and remodel the enhancer landscape 
during keratinocyte differentiation8. Overall, these data reveal that de novo binding of p63 to 
chromatin leads to global changes in the enhancer landscape, specifically, to the establishment of 
enhancers characterized by de novo chromatin accessibility and by H3K27ac flanking p63-bound 
sites. 
Figure 2.1. p63 remodels chromatin to establish enhancers A) Experimental setup showing 
inducible expression of p63 and downstream epigenomic analyses. B) Heatmap of p63 ChIPseq, 
ATACseq and H3K27ac ChIPseq (+/- 2.5kb from peak center) in control fibroblasts expressing an 
empty vector(ctrl) and in fibroblasts expressing p63 for 72 hours. C) Graph of called p63 peaks 
partitioned into open and closed chromatin according to ATACseq results in fibroblasts ctrl and 
fibroblasts + p63. D) Pie chart depicting differences in chromatin landscape at p63 called peaks in 
ctrl and after ectopic expression of p63 showing clear increase in chromatin accessibility (blue: 
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open) and H3K27ac (patterned lines). E) Distance to nearest TSS for all p63 peaks. F) 
Partitioning of p63 peaks into different genomic features. 
 
We examined the transcriptional consequence of these changes in the chromatin 
landscape, via RNA-seq after ectopic expression of p63 for 72 hours in fibroblasts. 1960 genes 
were upregulated upon ectopic expression of p63 (Fig 2.2a; fold change > 1.5 and FDR < 0.05), 
validating known p63 targets (IRF6, LCE1C, IVL, ITGB4 and SHH)26,27 and identifying over 1000 
genes previously not known to be regulated by p63 (full list in Supplementary Table 2.1). Gene 
ontology (GO) analysis of all upregulated genes showed enrichment of cell-cell adhesion 
categories characteristic of epithelial cells and important for epithelial lineage specification (Fig 
2.2a). Other categories were interferon, inflammation, and immune pathways (Fig 2.2a), 
consistent with previous reports showing p63 modulates epidermal development and 
inflammation programs, and plays a crucial role in T-cell development through establishment of 
the thymic epithelium28–31. Additionally, 1479 genes were downregulated upon expression of p63 
(Supplemental Fig 2.1d, fold change > 1.5 and FDR < 0.05), consistent with previous reports of 
p63 playing a repressive role at specific genes (COL6A2, CITED2, CDH13)27,28 and uncovering 
over 1000 new genes downregulated by p63.  
We compared changes in the chromatin landscape to transcription, finding chromatin 
accessibility and H3K27ac increased at enhancers and promoters of genes that became 
upregulated upon expression of p63 in fibroblasts (Fig 2.2b,c).  The largest fold change in 
chromatin accessibility was found at genes that became upregulated (Fig 2.2b, Supplemental Fig 
2.1e).  H3K27ac decreased at genes downregulated and increased dramatically at genes that 
were upregulated (Fig 2.2c, Supplemental Fig 2.1f). To validate these findings, we examined the 
previously known p63-regulated gene IRF621,32,33: the p63-dependent IRF6 enhancer showed de 
novo chromatin accessibility and H3K27ac, and establishment of this enhancer was accompanied 
by de novo activation of IRF6 expression in fibroblasts (Fig 2.1d). We also observed enhancer 
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establishment and transcriptional activation of genes encoding the F11 receptor (F11R) and 
integrin subunit alpha 7 (ITGA7) (Fig 2.2e, Supplemental Fig 2.1g). Thus, our data provide the 
first evidence that p63 can establish enhancers, revealing known and new gene targets of p63 
linked to epithelial cells and inflammation, and uncovering enhancers that might regulate their 
expression. 
Figure 2.2: p63 upregulates epithelial and inflammation genes downstream of enhancer 
establishment. A) Heatmap of z-scored RNAseq results for 1960 genes upregulated (fold 
change > 1.5 and FDR < 0.05) upon ectopic expression of p63, and top gene ontology categories 
showing enrichment of epithelial and inflammations categories among upregulated genes. B)C) 
Boxplots showing increased chromatin accessibility and H3K27ac at p63/KLF4 sites +/- 250bp 
near upregulated genes (* p-Value < 10E-10). D) UCSC genome browser tracks showing 
transcriptional activation of IRF6 and de novo H3K27ac and ATACseq signal at an enhancer 
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upstream of IRF6 in fibroblasts with ectopic expression of p63 (grey highlighted box). E) UCSC 
genome browser tracks showing transcriptional activation of F11R and de novo H3K27ac and 
ATACseq signal within introns of F11R in fibroblasts with ectopic expression of p63 (grey 
highlighted boxes). 
 
2.2.2: p63 and KLF4 co-establish keratinocyte specific enhancers to convert fibroblasts 
into keratinocyte-like cells.  
 These results demonstrate that p63 can establish chromatin structures required for 
expression of key epithelial specification genes.  However, previous findings show conversion of 
fibroblasts into keratinocyte-like epithelial cells requires co-expression of p63 and Kruppel-Like 
Factor 4 (KLF4), and these keratinocyte-like epithelial cells share significant morphology, 
functional characteristics, and gene expression patterns with basal epithelial keratinocytes34. To 
understand the molecular mechanisms and chromatin changes that underlie this crucial 
conversion, we extended our system to temporal co-expression of p63 and KLF4 in fibroblasts 
driven by the same doxycycline-induced promoter (see Fig 2.3a, Supplemental Fig 2.2a).  Indeed, 
keratin 14 (KRT14), a key biomarker of basal keratinocytes was upregulated only when p63 and 
KLF4 were co-expressed, and was not upregulated with expression of either p63 or KLF4 (Fig 
2.3a,2.3c, Supplemental Fig 2.2b). Our results thus confirm the requirement for both factors to 
achieve conversion of fibroblasts into keratinocyte-like cells. 
Broad GO analysis of the 2213 genes upregulated upon conversion showed high 
enrichment of gene classes encompassing epidermal development, cell adhesion, and other 
epithelial specific programs (Fig 2.3b, Supplementary Table 2.2). Many genes critical for 
keratinocytes, including FOXN1, DSC2 and DSG1, were newly expressed (Fig 2.3c and 
Supplementary Table 2.2), and others became upregulated over 1000-fold, including KRT14, 
KRT6a, GJB4 and LAD1 (Fig 2.3c). As with ectopic expression of p63 alone, approximately 1000 
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genes were downregulated with ectopic expression of p63+KLF4 (Supplemental Fig 2.2c, fold 
change > 1.5 and FDR < 0.05), including previously known repressed targets (CITED2, SATB2, 
TGFB1I1, SHOX2)27. Overall, the fold decreased enrichment and GO category specificity of 
downregulated genes was much lower compared to the upregulated genes (Supplemental Fig 
2.2c). Importantly, many key genes required for epidermal development and epithelial lineage 
specification were only upregulated in the combined system, including JAG2, GRHL3 and SFN 
(Supplemental Fig 2.2d, Supplementary Table 2), and, importantly, their dysregulation has been 
implicated in developmental malformations including skeletal dysplasias and orofacial 
clefting29,35,36. Additionally, the top 15 upregulated genes (via fold change p63+KLF4/ctrl) by the 
combined system includes keratinocyte specific genes (e.g. KRT6a, KRT14) that are key 
mediators of cell-cell adhesion programs (e.g. CDSN, LAD1, GJB4), as well as keratinocyte 
differentiation (e.g. TGM5, FA2H), all of which were not upregulated when p63 was expressed 
without KLF4 (Fig 2.3c).   
Figure 2.3: Ectopic co-expression of p63 and KLF4 convert fibroblasts into keratinocyte-
like cells. A) Immunofluorescence of p63 and KRT14 in fibroblasts + p63 and fibroblasts 
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+p63+KLF4 showing KRT14 is only upregulated when both p63 and KLF4 are expressed. B) 
Heatmap of z-scored RNAseq results for 2213 genes upregulated (fold change > 1.5 and FDR < 
0.05)  upon ectopic expression of p63+KLF4 showing high enrichment of epidermal and skin 
related GO categories. C) Comparison of transcriptional regulation of the top 15 genes 
upregulated in fibroblasts + p63+KLF4 showing both factors are required for upregulation of 
keratinocyte specific genes. 
 
To determine whether changes in transcription were a result of upstream enhancer 
establishment by p63 and KLF4, we induced expression of both proteins for 72 hours, followed by 
ATAC-seq and ChIP-seq of p63, KLF4 and H3K27ac. Our data revealed p63 bound to over 40K 
sites in the genome and KLF4 to approximately 25K sites (Fig 2.4a, Supplemental Fig 2.2e,2.2f). 
Because both proteins are needed for trans-differentiation, we hypothesized that co-bound sites 
might play a crucial role in establishing key keratinocyte-specific enhancers. Our ChIP-seq 
experiments revealed 13488 sites were co-bound by p63 and KLF4 (Fig 2.4a), primarily at 
intronic, intergenic and promoter regions (Supplemental Fig 2.2g,2.2h). Sites co-bound by p63 
and KLF4 showed a clear increase in chromatin accessibility at 80% of the sites, with 30% of the 
sites became newly open after ectopic expression of p63 and KLF4 (Fig 2.4b, Supplemental Fig 
2.2i), and 20% of shared sites became newly decorated by H3K27ac (Fig 2.4c, Supplemental Fig 
2.2i). Direct comparison of specific shared p63/KLF4 bound peaks in basal keratinocytes8 to 
fibroblasts, to fibroblasts + p63, and to fibroblasts + p63+KLF4 revealed highest similarity 
between H3K27ac marked enhancers in keratinocytes and those in fibroblasts +p63+KLF4 (Fig 
2.4d, Supplemental Fig 2.2j).  These results show p63 and KLF4 function together to establish 
chromatin structures concordant with those in basal keratinocytes.   
 Comparison of chromatin changes to gene expression revealed decreased chromatin 
accessibility at downregulated genes, as well as at genes that remained unchanged 
(Supplemental Fig 2.2j). Chromatin accessibility was increased only at promoters and enhancers 
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of genes becoming upregulated upon conversion (Fig 2.4e, Supplemental Fig 2.2k).  
Furthermore, H3K27ac decreased at genes that became downregulated, and profound increase 
in H3K27ac in upregulated genes, reaching more than 20-fold increase in converting cells 
compared to controls (Fig 2.4f, Supplemental Fig 2.2l). At the local level, a genome browser view 
of the KRT14 locus exemplifies these dramatic changes in chromatin landscape and transcription 
(Fig. 2.5a). In fibroblasts +p63+KLF4, establishment of enhancers occurred at intronic and 
intergenic regions around KRT14. The establishment of these enhancers was accompanied by a 
stark increase in KRT14 expression (Fig 2.5a).  As mentioned above, IRF6 is a key gene for 
CL/P, and KLF4 was also co-bound with p63 to the IRF6 enhancer with accompanying chromatin 
changes (Fig 2.5b).  
Figure 2.4: p63 and KLF4 co-establish keratinocyte specific enhancers. A) Venn diagram 
showing p63 and KLF4 are cobound in 13488 loci in the genome. B) Graph of p63/KLF4 peaks 
partitioned into open and closed chromatin according to peaks called from ATACseq showing 
increased chromatin accessibility after 72 hours at co-bound sites. C) Pie charts showing stark 
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increase in chromatin accessibility and H3K27ac at p63/KLF4 peaks. D) Heat map showing 
H3K27ac enrichment flanking p63/KLF4 peaks (+/- 2.5kb from peak center) shared in p63-
ChIPseq of basal keratinocytes, comparing fibroblasts, fibroblasts +p63, fibroblasts +p63+KLF4 
and reanalyzed basal keratinocyte data from8 E)F) Boxplots showing increased chromatin 
accessibility and H3K27ac at p63/KLF4 sites near upregulated genes (* p-Value < 10E-10). 
Figure 2.5: Local chromatin and transcriptional changes catalyzed by p63 and KLF4. A)B) 
UCSC genome browser tracks showing de novo H3K27ac and ATACseq signal at enhancer and 
promoter regions close to keratinocyte genes KRT14 and IRF6, as well as transcriptional 
activation (grey highlighted box). 
 
Overall, our results show p63 and KLF4 convert fibroblasts into keratinocyte-like cells via 
co-establishment of keratinocyte-specific enhancers. Specifically, p63 alone was able to establish 
epithelial enhancers to upregulate 32% of genes upregulated by p63 + KLF4 (710/2214 
upregulated genes) (Fig 2.1f, Supplementary Table 2.1, e.g. IRF6, F11R, ITGA7). However, 
importantly, both p63 and KLF4 were required to establish keratinocyte-specific enhancers and 
upregulate their respective genes, such as KRT14, KRT6A and JAG2. Because fibroblasts do not 
express p63, this trans-differentiation model constitutes a tractable system to investigate 
mechanisms underlying wild type and mutant p63 function in keratinocyte enhancer specification 
and to uncover key disease-specific processes. Because p63 represents a key transcription 
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factor driving epithelial specification and because p63 mutations are implicated in cleft lip palate 
and other orofacial developmental anomalies, we focused on further characterization of p63.  
 
2.2.3: Disease-specific p63 mutations found in patients with craniofacial malformations 
show defects in enhancer establishment.  
Heterozygous point mutations in the DBD and SAM domains of p63 have been shown to 
lead to limb and craniofacial malformations in human patients4–6. While mutations within the DBD 
are likely to be deleterious due to loss of DNA binding37–39, mutations within the SAM domain are 
likely to lead to dysregulation of protein-protein interactions needed for epithelial lineage 
specification40–42. 
We selected two point mutations for this study: p63R304W (Fig 2.6a, orange), a point 
mutation in the DBD occurring in patients with ectrodactyly ectodermal dysplasia cleft lip/palate 
syndrome (EEC)7 and p63I537T(Fig 2.6a, blue), a point mutation in the SAM domain found in 
patients with ankyloblepharon-ectodermal dysplasia and cleft lip/palate syndrome (AEC)39. Since 
characterized patients carry heterozygous p63 mutations, our homozygous model captures a 
severe scenario, with mutation of all p63 molecules within a tetramer; this approach allows 
investigation of substitution mutations in a simplified context.  
We introduced p63R304W (mtDBD) or p63I537T (mtSAM) into our inducible conversion 
system with co-expressed KLF4, for 72 hours (Fig 2.1a). Cellular immunofluorescence for KRT14 
revealed defects in conversion for both mutants (Fig 2.6b). As expected, the deleterious effects of 
mtDBD were most severe, showing no induction of KRT14 expression after 72 hours, whereas 
mtSAM showed reduced KRT14 expression compared to WT p63 (Fig 2.6b). RNAseq revealed 
that either substitution mutation poorly induced the top 15 genes upregulated by WTp63+KLF4, 
including epithelial-specific genes KRT6A, GJB4, LAD1 and CDSN (Supplemental Fig 2.3a; 
Supplementary Table 2.3). Further, among the 3367 differentially expressed genes in 
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WTp63+KLF4, nearly all failed to be induced in the mtDBD+KLF4 compared to control fibroblasts 
(Fig 2.6c). Hence, loss of p63 binding to DNA leads to complete loss of epithelial enhancer 
establishment in fibroblasts and nearly abrogates differential gene expression [16/3367 genes 
became upregulated (Supplementary Table 2.3)]. In contrast, mtSAM showed an intermediate 
expression pattern between WT+KLF4 and control fibroblasts, indicating specific defects in 
enhancer establishment and downstream epithelial gene induction (Fig 2.6c). Given this latter 
interesting specificity in defects, we focused on the SAM mutant p63I537T to dissect which 
deficiencies underlie the disease-specific phenotypes observed in AEC.  
 
Figure 2.6: Disease specific p63 mutations found in patients with craniofacial 
malformations show defects in converting fibroblasts to keratinocyte-like cells. A) Linear 
schematic of p63, showing domain structure and selected patient derived mutations B) 
Immunofluorescence of p63 and KRT14 in fibroblasts + fibroblasts +KLF4 and +WTp63, mtDBD 
or mtSAM showing KRT14 is not upregulated when the DBD is mutated and induction of KRT14 
is lower in mtSAM C) Heatmap of z-scored 3367 differentially expressed genes (fold change > 
1.5 and FDR < 0.05) between fibroblasts control and fibroblasts +p63+KLF4 showing mtDBD has 
almost no change in transcriptional profile and mtSAM shows a transcriptional profile in between 
fibroblasts ctrl and fibroblast +WTp63+KLF4. 
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We investigated the effect of the mtSAM on p63 binding genome-wide.  Among the 
13488 p63/KLF4 DNA binding sites in WTp63+KLF4 conversion (Fig 2.4a), most (71%; 9513) of 
the p63 binding peaks were retained in mtSAM+KLF4, and only 29% (3975) of p63 bound peaks 
were lost (Supplemental Fig 2.3b). The partial loss of mtSAM binding to DNA may be due to 
increased protein aggregation caused by SAM domain mutations within p6343. However, despite 
largely maintaining binding to DNA (Fig 2.7a, left panel), there was no increase in chromatin 
accessibility (Fig 2.7a, ATAC-seq) at retained mtSAM/KLF4 sites (Fig. 2.7a, 2.7b left). 
Furthermore, while most H3K27ac peaks were retained (Fig 2.7a), overall the amplitude of 
H3K27ac peaks increased only modestly compared to WT+KLF4 (Fig 2.7b right). Taken together 
with the observation that KLF4 binding is retained in the majority of these peaks (Fig 2.7a), these 
results suggest that the SAM domain of p63 is crucial for chromatin accessibility and 
establishment of H3K27ac in epithelial enhancer specification.  
We examined how these chromatin changes affect downstream gene regulation of the 
closest genes to p63/KLF4 bound sites. RNA-seq analysis revealed 50% of genes upregulated by 
p63/KLF4 were no longer upregulated in mtSAM (~1200 genes; Fig 2.7c), including key genes 
involved in craniofacial development, such as GRHL3, JAG2, LAMB3 and IRF6 (Supplemental 
Figure 2.3c, Supplementary Table 2.3). We assessed whether genes that were able to maintain 
activation in mtSAM/KLF4 had pre-existing enhancers, which might explain their continued 
expression.  Indeed, genes that maintained expression with mtSAM/KLF4 were near pre-
established and H3K27ac pre-decorated enhancers (Fig 2.7d left). In contrast, genes near newly 
established enhancers failed to be upregulated in mtSAM/KLF4 (Fig 2.7d right). Additionally, 
~200 genes were aberrantly upregulated in mtSAM/KLF4, including genes involved in craniofacial 
development in non-epithelial cell types, e.g. BMP2, VAX2 and GAD1 (Fig. 2.7b, Supplementary 
Table 2.3).  
At the local level, FOXN1 (Fig 2.7e), IRF6 (Fig 2.7f) and LAMB3 (Supplemental Fig 2.3d) 
showed defects in enhancer establishment despite retained binding of mtSAM and KLF4. In 
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particular, chromatin remained largely closed with mtSAM (in red highlighted box) and reduced 
H3K27ac flanking these sites, and these defects in establishing normal enhancer chromatin 
landscape lead to profound failure in upregulating associated genes FOXN1, IRF6 and LAMB3 
(Fig 2.7e,2.7f and Supplemental Fig 2.3a,2.3c). 
 
Figure 2.7: Mutations in the SAM domain of p63 found in AEC syndrome show defects in 
establishing enhancers and downstream activation of epithelial genes. A) Heatmap showing 
a stark reduction in chromatin accessibility (ATACseq signal) in mtSAM compared to WTp63, 
decreased H3K27ac and retained p63 and KLF4 binding. B) Box plots showing no increase in 
chromatin accessibility for mtSAM, as well as reduced enrichment of H3K27ac flanking p63/KLF4 
peaks. C) Venn diagram showing over 1000 genes are no longer upregulated in mtSAM+KLF4 
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and about 200 genes are upregulated de novo by this mutant. D) Box plots showing RNA-seq 
signal of genes close to p63/KLF4 retained peaks separated into peaks at pre-established 
enhancers in fibroblasts and newly established enhancers after ectopic expression of p63/KLF4. 
E)F) UCSC genome browser tracks showing defects (red boxes) in establishing open chromatin 
and inducing gene expression at FOXN1 and IRF6. 
 
Together our chromatin and transcription data show a dramatic difference in the roles of 
the DBD and the SAM domains of p63. The DBD is essential for enhancer establishment due to 
loss of function in DNA binding. Importantly, while the SAM mutant is able to bind to DNA, there 
are profound defects in both chromatin opening and establishment of H3K27ac, correlating with 
defective upregulation of proximal epithelial genes, Thus, because the SAM domain mutant I537T 
is found prominently in AEC syndrome, our results identify a potential explicit molecular 
mechanism, in which mtSAM drives pathogenesis through aberrant enhancer establishment 
(despite maintaining DNA binding) leading to low levels of specific critical craniofacial genes, 
such as IRF6, JAG2 and GRHL3. 
 
2.2.4: p63 regulates expression of critical genes associated with cleft lip/palate. 
While EEC and AEC are uncommon syndromes5,6, orofacial clefting is a key feature of 
these pathologies and clefting is a common developmental defect throughout the world11. Mouse 
genetic models (including knockouts of Trp63 and Irf6) have been crucial in understanding lip and 
palate development, however they do not fully recapitulate defects observed in human 
patients15,16. To date, 16 genes have been strongly implicated in nonsyndromic cleft lip+/- cleft 
palate (nsCL/P) via related phenotypes in mouse KO and knock down (KD) studies44 
(Supplementary Table 2.4a). Of the 16 reported genes, 5 were upregulated in our trans-
differentiation model (ESRP1, IRF6, FOLR1, FGFR8, WNT9B) (see Fig 2.5b, Supplemental Fig 
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2.2d, Supplementary Table 2.2 and Supplementary Table 2.4a), and ESRP1, IRF6 and FOLR1 
also showed robust dysregulation in mtSAM (Supplemental Fig 2.4a). Importantly, of these 
genes, only IRF6 was previously reported to be regulated by p6321,27,28, providing novel 
mechanistic insights into clefting pathogenesis via p63 mtSAM from our genome-wide study. 
Genetic Association Database studies45 of genes upregulated in our trans-differentiation 
model identified cleft lip and/or cleft palate as the most highly enriched disease associated 
category (Fig 2.8), with 76 associated genes identified, including genes known to cause nsCL/P 
(e.g.WNT9B, JAG2, and CDH1; full list in Supplementary Table 2.4b)29,35,46,47. Many of these 76 
genes have been identified as causal for orofacial clefting through human syndromes and family 
studies, while others are in proximity of SNPs involved in CL/P but are not known to be causally 
or functionally involved with orofacial clefting.  
 
Figure 2.8: Transdifferentiation model shows genes upregulated by p63 and KLF4 have 
been associated to cleft lip/palate. Genetic association database results showing cleft lip/cleft 
palate is the most enriched disease category among the 2213 genes upregulated (fold change > 
1.5 and FDR < 0.05)  by p63 and KLF4. 
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To date, genome-wide association studies (GWAS) and other approaches have identified 
40 human risk loci for nsCL/P with conclusive evidence (Supplementary Table 2.4c)14,17–20. These 
40 loci are estimated to explain about 25% of the heritability reported for nsCL/P. However, the 
causative genes and mechanisms at the majority of these loci are unknown. While previous 
studies have shown the importance of neural crest cells in CL/P development14, different tissue 
systems are expected to contribute to this complex disease. In particular, keratinocytes from 
patients with CL/P have recently been reported to display differentiation defects48–51. Based on 
the key observation that p63+KLF4 establish enhancers to regulate keratinocyte specific genes, 
including critical craniofacial genes (see Supplemental Fig 2.2d, Supplementary Table 2.2), we 
investigated the genes located within the topologically associated domain (TAD)52,53 overlapping 
each of the 40 risk loci. The reasoning to examine gene association within TADs is because gene 
regulatory enhancer-promoter contacts occur primarily within TADs52–54.  We found that within the 
associated TAD of 17 of these risk loci, at least 1 gene, and a total of 37 genes were upregulated 
in our trans-differentiation model (Fig 2.9, Supplementary Table 2.4c). We conclude that crucial 
regulatory interactions occur within TADs encompassing genes induced by p63/KLF4. 
                                                                      
Figure 2.9: p63 and KLF4 upregulate genes within TADs containing cleft lip/palate risk loci. 
40 identified risk loci for cleft lip/palate indicated by black lines at the respective chromosomes 
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with dark blue circles at TADs containing at least 1 gene upregulated by both p63 & 
KLF4(respective genes in dotted triangles). 
 
To analyze whether any of the 37 genes (Fig 2.9b) located at the risk loci and/or their 
enhancer regions might contribute to nsCL/P, we used SNPs and their p-values from a recent 
GWAS on nsCL/P14 to compute gene-based association p-values using 
MAGMA55(Supplementary Table 2.4d). We first validated our approach by examining genes 
upregulated by p63+KLF4 within and outside of the 40 risk loci that have been shown to cause 
nsCL/P21,47,56. We identified significant p-values for known causal genes within the 40 risk loci, 
such as in the 1q32 locus (IRF6), 17q21 (WNT9B) and 8q22.1 (ESRP1)  loci (Fig 2.10, red). Our 
approach also identified significant p-values for known causal genes outside of the risk loci, 
including JAG2, CDH1, and CTNND129,46,57 (Fig 2.10, red with *).  
 
 
Figure 2.10: p63 regulates expression of critical genes associated with orofacial clefting. 
List showing association values of top 10 genes calculated by gene-based analysis with MAGMA 
as implemented in FUMA73 in the following categories: (red) genes known to cause CL/P with * 
marking genes outside of the known 40 risk loci; (green) CL/P candidate genes located at 40 risk 
loci with significant (p<0.05) association to CL/P and (blue) new candidate genes associated with 
CL/P outside of known risk loci. 
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Within the 40 risk loci we identified 10 candidate genes upregulated by p63 with 
significant gene based association p-values to nsCL/P (p-value<0.05), including SEMA4D, 
BEST3, ZFP36L2, and KRT4 (Fig 2.10, green). Interestingly, in three of the risk loci, our data 
point towards a risk gene for nsCL/P that is different from the gene previously suggested: At 
2p21, THADA was previously suggested to be the risk gene58, our data suggests it is ZFP36L2 
(p<0.05) (Fig 2.10, green with *), a gene shown to play a role in basal keratinocytes59. At 2p25.1 
KLF11 had been suspected to be the nsCL/P risk gene, our data suggests it is GRHL1 (p<0.5) a 
close family member of GRHL3, a well-established risk gene for cleft palate60,61. Further, at risk 
loci 9q22.2 our data prioritize SEMA4D (p<10E-05) (Fig 2.10, green with *) instead of 
GADD45G61, as the probable nsCL/P risk candidate. 
Finally, to identify novel risk loci and novel causal candidate genes for nsCL/P, we 
extended our gene based association p-value study to genes upregulated in our trans-
differentation model outside of the known 40 risk loci. We identified 111 novel candidate genes 
showing high association to nsCL/P (p-values <0.05 computed as above, Supplementary Table 
2.4d). Several identified genes, including ZNF296, CPNE9, ITGB4, and ZNF750 (Fig 2.10, blue) 
play key roles in epithelial cells but have no known role in CL/P. Regional association plots for 
ZNF296 and CPNE9 demonstrating the local association structures at these genes in the GWAS 
data reveal SNPs with nominal statistical significance at each of these genes and also in the 
surrounding non-coding areas (Fig 2.11a,b). The location of these SNPs  suggest that common 
genetic variants within or near these genes regulated by p63 might alter gene function or 
expression and, thus, may contribute to nsCL/P, but the genes have escaped detection in genetic 
studies due to lack of statistical power (such as sample size).   
 Overall, our trans-differentiation model in human cells provides an orthogonal approach 
to identify candidate genes in nsCL/P directly regulated by p63. Indeed, even at established risk 
loci, we have used our approach to find key p63-regulated genes, as the most likely CL/P-
associated genes (e.g. ESRP1, GRHL1, RHPN2, and ARID3B). Further we use this approach to 
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identify new nsCL/P specific candidate genes and the enhancers that regulate them (e.g. 
ZNF296, CPNE9, ITGB4, and TDRP). 
 
Figure 2.11: Transdifferentiation model reveals novel nsCL/P candidate genes and the 
enhancers that regulate them. A)B) Regional association plots of ZNF296 and CPNE9, 
showing  nsCL/P associated SNPs with nominal significant gene-based p-value (<0.05) within the 
genes and up to 200kb away from transcription start sites. 
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2.2.5: SNPs associated with cleft lip/palate are highly enriched in enhancers established 
by p63 and KLF4 
 GWA studies of SNPs have identified several genetic variants strongly associated to 
nsCL/P14,17–20. Many of these disease-associated SNPs are located outside of exons, thus 
suggesting a gene expression regulatory role, such as enhancers and promoters. Since orofacial 
clefting is a major phenotype in patients with point mutations in p63, and, as we show here, since 
p63 plays a key role in establishing epithelial enhancers, we explored potential overlap between 
p63 binding sites and nsCL/P-associated SNPs identified in GWA studies. We curated three lists 
of p63 binding sites: (A) all p63 peaks in fibroblasts +p63; (B) all p63 peaks in fibroblasts 
+p63+KLF4; (C) p63/KLF4 shared peaks in fibroblasts +p63+KLF4 (i.e. a subset of (B)). Using 
the same GWAS dataset as above14 and the enrichment-tool GREGOR62, we determined that list 
C - p63 peaks co-bound by KLF4 - showed strongest enrichment of nominal significant (p<0.05) 
nsCL/P SNPs (Fig 2.12a). We focused on H3K27ac flanking these sites as a mark of active 
enhancers, partitioning H3K27ac peaks into enhancers that are preestablished (already marked 
by H3K27ac in fibroblasts) or into new enhancers (only become marked by H3K27ac after 
fibroblast to keratinocyte-like conversion) (see Fig 2.4c, 2.4d). Enrichment analysis showed 
significant enrichment (p<0.05) of nominal significant nsCL/P SNPs only for newly established 
enhancers (Fig 2.12a). 
 Based on the results from GREGOR we performed colocalization analysis of nsCL/P 
SNPs, focusing on the p63/KLF4 shared peaks14. This analysis further accounts for the strength 
of association to nsCL/P of each SNP, with highly associated  SNPs contributing to a lower 
overall co-localization p-value (see Methods). We observed significant colocalization (p-value 
<0.05) for p63/KLF4 peaks in which active enhancers are established (newly marked by 
H3K27ac),  whereas shared p63/KLF4 peaks at preestablished enhancers and peaks without 
H3K27ac did not achieve statistical significance (Fig 2.12b).  
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We next focused on H3K27ac peaks - which are broader than p63/KLF4 peaks - because 
SNPs close to, but outside of p63/KLF4 peaks, might be in linkage disequilibrium and contribute 
to risk of CL/P. We performed colocalization analysis of nsCL/P SNPs in H3K27ac peaks in 
control fibroblasts, in preestablished enhancers, and in new enhancers flanking p63/KLF4 peaks 
(Fig. 2.12c). Here only enhancers newly established by p63/KLF4 showed strong colocalization 
(p-value <10E-4) (Fig 2.12c),  confirming the results obtained in the GREGOR analysis. 
 
Figure 2.12: SNPs associated with non-syndromic cleft lip with or without cleft palate are 
highly enriched in enhancers established by p63 and KLF4. A) GREGOR analysis showing 
p63/KLF4 shared peaks (green) and newly established H3K27ac (orange) flanking these peaks 
are significantly (p<0.05) enriched for SNPs associated to nsCL/P. B) Co-localization of shared 
p63/KLF4 peaks at inactive/preestablished/new enhancers, with nominal significant nsCLP 
associated GWAS SNPs. Graph shows only p63/KLF4 peaks flanked by de novo H3K27ac peaks 
are enriched for nsCL/P associated SNPs. C) Co-localization of H3K27ac peaks with nominal 
significant nsCLP associated GWAS SNPs. Graph shows only new enhancers in converted cells 
flanking p63/KLF4 peaks are significantly enriched for nsCL/P associated SNPs. 
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 Genome browser views overlaid with nsCL/P SNPs allowed visualization of the high 
colocalization of SNPs at p63/KLF4 peaks and newly established enhancers (ATAC-seq and 
H3K27ac peaks) close to MAFB (Fig 2.13a), at the known 8q24 risk locus63 (Fig 2.13b), at the 
nsCL/P causing gene IRF6 (Supplemental Fig 2.5a) and near RHPN2 (Supplemental Fig 2.5b). 
Importantly, the genes downstream of these regulatory elements are activated in our trans-
differentiation model (see RNA-seq in Fig 2.13a,b and Supplementary Fig 2.5a,b), indicating they 
are upregulated by establishment of new enhancers by p63/KLF4.  
 
Figure 2.13: Enhancers established by p63 and KLF4 at MAFB and the 8q24 locus are 
enriched for SNPs associated with nsCL/P. A) and B) Overlay of SNPs and UCSC genome 
browser tracks highlighting in orange that p63/KLF4 peaks strongly colocalize with highly 
associated nsCL/P SNPs near MAFB and the known 8q24 locus, in grey binding of both proteins 
at promoters. 
 
Overall, GREGOR analysis and colocalization results show enhancers established by 
p63/KLF4 are highly enriched for SNPs associated with nsCL/P. These SNPs likely affect 
downstream expression of epithelial specific genes and lncRNAs required for proper lip and 
palate development, as observed with IRF6 and mutations in an upstream regulatory element of 
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this gene established by p6321. Thus our unbiased trans-differentiation model in conjunction with 
GWAS data provides an independent method to identify driver genes. The method also provides 
novel mechanistic insights into how nsCL/P-related SNPs might be regulating pathogenesis via 
disruption of p63/KLF4 binding sites crucial for enhancer establishment and downstream gene 
regulation. 
 
2.3: Discussion 
Here we report a trans-differentiation model as a novel approach to determine the role of 
p63 in craniofacial development. We show that p63 can establish epithelial enhancers to regulate 
downstream genes and that this process is disrupted when p63 carries mutations derived from 
human disease. In particular, our results show a novel mechanism underlying pathogenic p63 
mutations, in which failure to open and establish enhancers leads to transcriptional dysregulation. 
We integrate our epigenomic data with GWAS datasets derived from nsCL/P patients to identify 
novel CL/P candidate genes regulated by p63. We also uncover strong enrichment of nsCL/P-
associated SNPs at enhancers established by p63, providing mechanistic insight into how these 
SNPs lead to human pathogenesis.  
A key role of transcription factor p63 in mediating epidermal commitment, development, 
and differentiation has been extensively demonstrated through mouse models and causative 
point mutations in human disease. In mice, knockout of p63 leads to developmental and 
morphological defects in the squamous epithelia and epidermis, causing abnormal craniofacial 
development, truncated limbs, and loss of salivary glands, hair follicles, and teeth2,3. To date, how 
p63 engages and modifies chromatin to promote normal development during these early stages 
is still being elucidated. Here, we report key observations that p63 can establish enhancers and 
that defects in this process may underlie human craniofacial malformations.  
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Previous studies of p63’s engagement with chromatin have focused on its role in 
keratinocyte differentiation8,10,51,64,65, while de novo engagement with chromatin has not been 
extensively addressed due in part to lack of tractable human models. Thus, to examine the first 
encounter of p63 with chromatin, we expressed p63 ectopically in a temporally controlled manner 
in human BJ fibroblasts, a cell line that does not express p63. We show p63 establishes 
enhancers to upregulate epithelial and inflammation genes. We next developed an inducible 
trans-differentiation model based on published reports showing p63 co-expressed with KLF4 can 
convert fibroblasts into keratinocyte-like cells34. We determined that co-binding of p63 and KLF4 
leads to robust establishment of enhancers that correspond remarkably well to bone fide 
enhancers in basal keratinocytes. Thus, this model system recapitulates the epigenetic conditions 
of early epithelial development.  
Mutations in the p63 DBD in EEC patients have been previously shown to cause loss of 
downstream transcriptional activation of known p63 targets40,51,66. Further studies showed that 
p63 mutations in AEC also disrupted transcription and caused p63 aggregation43,40–42. In 
particular, it has been proposed that aggregation of p63 in AEC leads to decreased binding of 
p63 to its DNA targets and that this is a key underlying disease mechanism 43. However, it 
remains unclear how enhancer regulation by p63 is altered by substitution mutations. Our 
approach shows that one prevalent substitution mutation in the DBD leads to complete loss of 
p63 binding to chromatin and loss of enhancer establishment. On the other hand, one frequent 
substitution mutation in the SAM domain largely retains DNA binding but results in defects in 
chromatin opening, causing dysfunctional enhancer establishment and defective upregulation of 
key craniofacial genes. These results suggest the SAM domain is involved in recruiting chromatin 
remodelers to displace nucleosomes and establish open chromatin, in line with previous reports 
suggesting p63 and the BAF complex cooperate to open chromatin during epidermal 
differentiation64. Further experiments are required to identify proteins interacting with the SAM 
domain of p63 to perform these functions. However, our results point towards a novel function of 
the p63 SAM domain, as well as a novel molecular mechanism underlying AEC.  
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While EEC and AEC are relatively rare, one phenotype of both syndromes is cleft lip 
palate, which also occurs in the absence of p63 mutations in 1:700 births11.  A connection 
between p63 and CL/P has previously been proposed32,67,68, however, these studies were largely 
carried out in mice, a model in which KO and KD of p63 does not accurately recapitulate clefting 
of the lip or palate2,3. This could be in part due to extensive rewiring of the p63 response element 
network between mouse and human, as well as human specific craniofacial enhancers that were 
recently reported69,70. Further, mouse models of known disease-causing genes such as IRF6, 
PVRL171, and CDH146 in human also fail to recapitulate clefting of the lip15,16,35,44, suggesting 
stark differences in these processes between species and highlighting the need for orthogonal 
human approaches. In humans, GWAS and other approaches have identified 40 human risk loci 
for nsCL/P with conclusive evidence. These 40 loci represent about 25% of heritability in nsCL/P 
cases reported, however at the majority of these loci, the causative variants and mechanisms are 
unknown, due in part to a lack of mechanistic data within non-coding regions. Thus, by integrating 
epigenomic datasets from our trans-differentiation keratinocyte model with GWAS datasets, we 
gained novel insights into molecular mechanisms underlying nsCL/P.  
Overlapping of our results with GWAS datasets from nsCL/P identified key known 
candidate genes regulated by p63  and newly established enhancers at known risk loci, including 
IRF6 in the 1q32 locus and WNT9B at 17q21.32. Importantly, we identified ZFP36L2 and GRHL1 
at 2p21 and 2p25.1 respectively as the lead risk nsCL/P genes despite previous reports focusing 
on other genes in those loci58,61. Our data also prioritized ESRP1 and SEMA4D, known genes in 
epithelial regulation, as nsCL/P risk candidates at 8q22.1 and 9q22.2 loci in which the risk genes 
had not been identified. Knockout studies of ESRP1 in particular showed full penetrance of CL/P 
in mice56. Further, by combining GWAS datasets with genes upregulated in our trans-
differentiation model, we identified over 100 new candidate genes and risk loci for nsCL/P 
validation studies, including ZNF296, CPNE9, and ITGB4. These genes play important roles in 
epithelial cells but their role in nsCL/P had, prior to our study, been unknown.  
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In addition to identifying genes downstream of p63, our analysis also identified the 
enhancers that regulate them. For instance, FOLR1 and FOLR3 were both upregulated in our 
trans-differentiation model following establishment of upstream enhancers by p63 and KLF4. 
Knockout of the mouse homolog of FOLR1 gene was shown to lead to orofacial clefting72; 
however, mutations in these genes have not been found in humans with CL/P. It is possible that 
previously uncharacterized mutations at the enhancers of these genes may increase risk of CL/P, 
which could be mitigated by folic acid supplementation, as is the case in mouse models with KO 
of folbp172. 
Finally, using two different co-localization analyses, we found that enhancers established 
by p63+KLF4 are enriched for SNPs associated with nsCL/P, providing a novel molecular 
mechanism for how these SNPs may contribute to disease at a molecular level. For instance, at 
the nsCL/P risk loci 20q12, MAFB has been proposed to be the main risk gene for nsCL/P12,73. 
However, no functional or mechanistic data has supported this claim. Our integrated data shows 
p63 and KLF4 co-bind and establish enhancers upstream of MAFB, leading to robust de novo 
expression of MAFB. These enhancers are enriched for nsCL/P associated SNPs, providing a 
novel mechanism underlying how these SNPs may affect proper expression of MAFB during lip 
and palate development. Another example is the known 8q24 risk locus, which shows the 
strongest effect size across populations of Asian and European origin63,74. Previous reports 
conducted in murine models suggested that this region contains enhancers important for MYC 
regulation75; however, deletion of this region resulted in clefting of the lip or palate in less than 7% 
of murine embryos, despite robust downregulation of MYC. Our data shows this region contains a 
number of p63+KLF4 bound and established enhancers that are enriched for SNPs associated 
(p<5.0E-8) with nsCL/P. Further, we show establishment of enhancers in this region lead to 
upregulation of a long noncoding RNA LINC00977 which is not present in mice. In human 
keratinocytes, it was previously observed that knockdown of p63 leads to downregulation of 
MYC76. Thus, it is possible that p63 regulates enhancer establishment at 8p24 to upregulate 
LINC00977 and modulate MYC expression during lip and palate development. While  mechanistic 
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experiments are necessary to confirm this, our data provide novel candidate disease mechanisms 
underlying nsCL/P. 
Taken together, our findings address how p63 binds and remodels chromatin with its first 
encounter, identifies and prioritizes nsCL/P candidate genes and the enhancers that regulate 
them, and provides new explanations for how p63 mutations and SNPs associated with nsCL/P 
underlie disease.  
 
2.4: Materials and methods 
2.4.1: Cell culture 
 BJ foreskin fibroblasts (CRL-2522) were obtained from American Type Culture Collection 
(ATCC), and were cultured in a 37˚C incubator at 3% oxygen, in tissue culture medium containing 
DMEM with 10% FBS, 100µg/ml streptomycin and 100 units per ml penicillin. 
2.4.2: Lentivirus and retrovirus infection 
 Stable cell lines were made by lentivirus and retrovirus infection, as previously 
described74. Tetracycline On System was introduced in two steps. First the reverse tetracycline-
controlled transactivator (rtTA) was introduced via lentivirus Lenti CMV rtTA3 Blast (w756-1) 
(Addgene plasmid #26429). Lentivirus was transfected with packaging plasmids to HEKT293T 
cells, viral supernatant was filtered through a 0.45µm filter, supplemented with 8µg/ml polybrene, 
and mixed with trypsinized BJ cells for 24 hours. Cells were selected for 1 week using blasticidin 
at 4µg/ml. 
We then cloned ∆NP63alpha-Flag (Addgene plasmid #26979) and ∆NP63α-Flag cloned with a 
T2A self-cleaving peptide linker to human KLF4 (plasmid #19777) into a retroviral construct 
pRetroX-TRE3G-puro construct. We introduced point mutations (I537T and R304W) into p63 via 
Quick Change II site directed mutagenesis from Agilent (Catalog # 200523). Retrovirus constructs 
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were transfected to Phoenix packaging cell line, purified and used as described above. Infected 
cells were selected with puromycin for approximately a week. 
 
2.4.3: Trans-differentiation  
 BJ stable cell lines infected with rtTA and either an empty pRetrox-TRE3G vector, 
pRetrox-TRE3G-∆NP63α-Flag or pRetrox-TRE3G-∆NP63α-Flag-T2A-hKLF4 were induced for 72 
hours using 1ug/ml doxcycycline replenished every 24 hours. A low dose of hydroxyurea (HU) 
1mM was added after 24 and 48 hours, as we observed this improves conversion without 
affecting control cells. Cells were then collected for western blot, ATAC, RNA and ChIPseq. 
2.4.4: Western Blot 
Cells were lysed in RIPA buffer containing 1% NP-40, 150mM NaCl, 50mM Tris-Cl, pH 
8.0 and 1% SDS supplemented with cOmplete, EDTA-free protease inhibitor (Roche 
11873580001). Protein concentration was determined by BCA protein assay (Life technologies, 
#23227), after which equal amount of proteins were loaded and separated by polyacrylamide 
gels. Proteins were then transferred to nitrocellulose membranes. Antibodies used in this study 
were as follow: Flag (Sigma, M2, F1804), hKLF4 (R&D Systems, AF3640), p63 (Cell Signaling 
Technology, D2K8X), GAPDH (Fitzgerald, 10R-G109a) and KRT14 (Abcam, ab7800). 
2.4.5: Immunofluorescence 
 Trans-differentiated and control fibroblasts grown on cover glasses were fixed in 4% 
paraformaldehyde in PBS for 30min. Cells were then washed twice with PBS, and permeabilized 
with 2.5% Triton X-100 in PBS for 10min. After two washes, cells were blocked in 10% BSA in 
PBS for 1 hour at room temperature. Cells were then incubated at 4˚C overnight with primary 
antibodies in 5% BSA in PBS with 0.1% Tween 20 (PBST). Primary antibodies used were: Flag 
(Sigma, M2, F1804), hKLF4 (R&D Systems, AF3640), p63 (Cell Signaling Technology, D2K8X) 
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and KRT14 (Abcam, ab7800). The next day, cells were washed 4x10min with PBST, followed by 
incubation with Alexa Fluor-conjugated secondary antibodies (Life Technologies) in 5% BSA in 
TBST for 45 minutes at 37˚C. Cells were then washed 3x10min in PBS, incubated with 0.5µg/ml 
DAPI in PBS for 5 min, and washed twice with PBS. The slides were then mounted using 
VECTASHIELD antifade mounting medium (H-1000, vector Laboratories) and incubated 
overnight in the dark at room temperature. The slides were then imaged with a Nikon Eclipse 80i 
fluorescent microscope. 
2.4.6: Chromatin immunoprecipitation and RNA preparation 
Trans-differentiated and control BJ fibroblasts (population doubling 20-30) were 
crosslinked with formaldehyde (1% final) for 5 min at room temperature or lysed in TRIzol 
(ThermoFischer Scientific, #15596018) and snap frozen for RNA isolation. Crosslinked cells were 
quenched with glycine (125mM final) for 5 min, followed by 2 x washes in cold PBS. Nuclei were 
then isolated from 20 million cells as previously described75, and chromatin  was sheared to 
250bp average size using a Covaris S220. Immunoprecipitations were performed using 500µg 
sheared chromatin lysate and 5 µg antibodies preconjugated to Protein G beads (Invitrogen): 
H3K27ac (Active Motif, 39133), Flag (Sigma, M2, F1804) and hKLF4 (R&D Systems, AF3640). 
ChIP reactions were incubated for 16 hours at 4˚C with rotation and then washed 4x in wash 
buffer (50mM HEPES-HCl pH 8, 100mM NaCl, 1mM EDTA, 0.5mM EGTA, 0.1% sodium 
deoxycholate, 0.5% N-laurylsarcosine), followed by 1 wash in ChIP final wash buffer (1xTE, 
50mM NaCl). Immunoprecipitated DNA was eluted from washed beads, reverse crosslinked 
overnight, purified and used to construct libraries. Snapfrozen RNA samples were further 
extracted using chloroform and QIAGEN RNeasy Mini Kit (#74106) including DNase digestion. 
Purified RNA was then reverse transcribed to cDNA using High Capacity cDNA Reverse 
Transcription Kit from Applied Biosystems (4368814), cDNA was then quantified and used to 
construct sequencing libraries. 
2.4.7: ChIP/RNA sequencing and data analysis 
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Sequencing libraries for ChIP experiments were prepared using NEBNext Ultra reagents 
(New England Biolabs). All ChIP samples and input were double-end sequenced on an Illumina 
NextSeq 500. Reads were mapped to the reference human genome assembly GRCh37/hg19 
using Bowtie2 (maximum fragment size set to be 2000 bp). Properly aligned, non-duplicated pairs 
were retained for peak calling using MACS2 (q-value cutoff set to be 0.01). Fragment pileup per 
million reads for each ChIP library and corresponding input were also generated and subtracted 
by MACS2 for visualization. Only overlapping peaks shared by biological replicates were used for 
analysis.  
Poly(A) + RNA was isolated using double selection with poly-dT beads, followed by first 
and second-strand synthesis. Reads were mapped to the reference human genome assembly 
GRCh37/hg19 using splice-aware tool STAR (maximum fragment size set to be 2000 bp). 
Alignments with a MAPQ score over ten were counted towards RefSeq genes using 
featureCounts (default parameters). Fragment pileup per ten million reads for each RNA library 
were generated by BedTools (“genomecov -split -bg -scale”) and UCSC tool package 
(“bedGraphToBigWig”). Pairwise differential expression analysis was implemented using R 
package DESeq2 with FDR cutoff set to be 0.05 and fold-change cutoff set to be 1.5.  
2.4.8: Assay for transposase-accesible chromatin (ATAC-seq) 
ATACseq experiments were performed as previously described76 using 100,000 cells and 
5µL Tn5 transposase (Nextera XT Kit, Illumina) to tagment intact nuclei. Reads were mapped to 
the reference human genome assembly GRCh37/hg19 using Bowtie2 (maximum fragment size 
set to be 2000 bp). Properly aligned, non-duplicated pairs were retained and reads mapped to 
mitochondria or ENCODE blacklist regions were excluded. For peak calling, we adjusted the read 
start sites to represent the center of the transposon binding event (all reads aligning to the + 
strand were offset by +4 bp, and all reads aligning to the - strand were offset -5 bp). Broad peaks 
were called using MACS2 (q-value cutoff set to be 0.01). Fragment pileup per million reads for 
each ATAC library were also generated by MACS2 for visualization. Similar to the ChIP-seq data, 
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only overlapping peaks shared by biological replicates were used for analysis. To acquire sub-
nucleosomal peaks, only fragments shorter than 120 nt were used. 
 
 
2.4.9: Gene ontology analysis 
 GO terms of differentially regulated genes were determined using DAVID. We selected 
the top 10 GO categories based on the lowest FDR. 
2.4.10: Intersection 
All p63 peak sets were combined by taking the union using BedTools (“bedtools merge”) 
and categorized into different subsets based on whether they overlap with ATAC-seq or ChIP-seq 
peaks (overlap by at least 1bp). Peaks were annotated to genes by the nearest RefSeq TSS 
using HOMER (default parameters for “annotatePeaks” command). Motif analysis was 
implemented using HOMER (“findMotifsGenome -size given”).   
2.4.11: Statistical analysis 
 Metaplots and heatmaps centered around any peak set were generated using DeepTools  
(“computeMatrix” and “plotHeatmap”). ChIP-seq or ATAC-seq signal over each peak region was 
computed using Bwtool (unit: per million reads per kb) in order to generate boxplots and bar 
graphs, and Mann-Whitney test was applied unless otherwise specified. 
2.4.12: Analysis of GWAS-data for nsCL/P 
GWAS-data for nsCL/P were retrieved from a previously published study14 which had 
included 399 cases, 1.318 controls and 1.461 case-parent trios. The SNP data comprised about 
8.01 million common variants at a minor allele frequency (MAF) > 1%. All analyses for the 
present manuscript were performed using the overall data, i.e., without stratification for ethnicity.  
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2.4.13: Gene-based p-values.  
 While single variants alone might be statistically underpowered to show significant 
effects, their contribution in sum can be analyzed by aggregating individual variants within a 
predefined region (for instance, genes). Based on the p-values obtained from the nsCL/P GWAS 
we used MAGMA (v1.06)51 a principal-component-based regression framework that allows for 
gene-based analysis. We run the gene-based analysis for the p63 upregulated genes (n=250) as 
implemented in the FUMA online tool (Functional Mapping and Annotation of Genome-Wide 
Association Studies) platform (v1.3.2)73, with default parameters (SNP-wide mean model) and 
with the 1000 Genome Phase3 as reference panel. In the gene set analyses, curated gene sets 
and GO terms from MsigDB are tested. For FUMA (≥ v1.3.1), 10655 gene sets (curated gene 
sets: 4738, GO terms: 5917) from MsigDB v6.1 are used. Bonferroni correction was performed for 
the all tested gene sets. 
2.4.14: Enrichment analyses 
 To evaluate the enrichment of all nominal significant nsCL/P GWAS SNPs70 in à priori 
selected regulatory elements, the GREGOR (v1.4.0)58 software tool was used. Selection of the 
regions was performed based on the presence of p63 and/or KLF4 and/or H3K27ac peaks. For 
analysis of overlay of specific SNPs to specific elements, a colocalization approach was 
performed as previously suggested14. Briefly, SNPs were mapped to either “positive regions” (i.e., 
in p63+KLF4 +/- H3K27ac binding regions) or “negative regions” (all others) and then grouped 
into nine categories 10-k+1 ≥ P > 10-k for k = 1, . . ., 8 and 10-8 ≥ P. The frequencies of SNPs being 
located in the positive regions and those outside the annotated regions were counted within each 
category. The one-sided Cochran-Armitage trend test was applied in R environment with function 
prop.trend.test of stats package to test for an enrichment of smaller P-values within annotated 
regions on the basis of the resulting 9×2 contingency table. 
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2.5:	Supplemental	Figures	
	
	
Supplemental Figure 2.1: Ectopic expression of p63 in fibroblasts leads to establishment 
of enhancers and downstream upregulation of inflammation and epithelial genes. A) 
Western blot showing p63 ectopically expressed in fibroblasts reaches an expression level 
comparable to endogenous levels observed in undifferentiated normal human epidermal 
keratinocytes after 48h B) Alluvial plot depicting changes in chromatin state after ectopic 
expression of p63 at p63 bound peaks for chromatin transitions with >200 peaks. C) Heatmap 
showing high overlap between newly accessible chromatin (ATACseq) in fibroblasts + p63 and 
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published MNaseSeq in human fibroblasts25. D) Heatmap showing 1479 downregulated genes in 
fibroblasts + p63 compared to control and GO categories enriched among downregulated genes. 
E)F) Boxplots showing increased chromatin accessibility and H3K27ac across downregulated, 
unchanged and upregulated genes in fibroblasts + p63, with the highest fold change for 
upregulated genes (*p-Value<10E-5, **p-Value<10E-16). G) UCSC genome browser tracks 
showing transcriptional activation of ITGA7 and de novo H3K27ac and ATACseq signal within 
introns of ITGA7 in fibroblasts with ectopic expression of p63 (grey highlighted boxes) 
	
Supplemental Figure 2.2: Ectopic co-expression of p63 and KLF4 leads to establishment of 
keratinocyte specific enhancers and upregulation of epithelial genes. A) Western Blot 
showing robust co-expression of p63 and KLF4 in the inducible trans-differentiation model 
(fibroblasts+p63+KLF4) B) Western Blot showing KRT14 is only upregulated when both p63 and 
KLF4 are expressed and not in control fibroblasts, fibroblasts + KLF4 or +p63 alone. C) Heatmap 
showing 1154 downregulated genes in fibroblasts + p63+KLF4 compared to control and GO 
categories enriched among downregulated genes. D) Heatmap showing co-expression of p63 
and KLF4 is required for upregulation of a subset of key epithelial and craniofacial genes. E) 
Distance to nearest TSS for all p63 and all KLF4 peaks in fibroblasts +p63+KLF4. F) Partitioning 
of p63 and KLF4 peaks into different genomic features showing intergenic and intronic regions 
are the most abundant for both G) Distance to closest TSS for p63/KLF4 shared peaks. H) 
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Partitioning of 13488 p63/KLF4 shared peaks showing enrichment of intronic and intergenic 
regions, consistent with enhancers. I) Alluvial plot depicting changes in chromatin state after 
ectopic expression of p63 and KLF4 at p63/KLF4 bound peaks for chromatin transitions with 
>200 peaks. J) Boxplot showing H3K27ac is not statistically different (p=0.01) at shared p63 
peaks between p63+KLF4 in fibroblasts and p63 in undifferentiated keratinocytes (ChIP-seq 
signal at p63 peaks (n=4981) +/- 500bp) (**p-Value<10E-16) K)L) Boxplots showing increased 
chromatin accessibility and H3K27ac only at genes upregulated in fibroblasts + p63+KLF4 (*p-
Value<0.05, **p-Value<10E-16). Very high fold change in H3K27ac at p63/KLF4 peaks close to 
upregulated genes. 
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Supplemental Figure 2.3: Mutations in p63 disrupt enhancer establishment and lead to 
loss of upregulation of key keratinocyte specific genes. A) Heatmap showing mtDBD and 
mtSAM have disrupted or loss of upregulation of the top 15 genes upregulated by WTp63+KLF4. 
B) Category plot showing 71% (9513/13488) of p63/KLF4 sites are retained when p63 carries 
mutations in the SAM domain. C) Heatmap showing mtDBD and mtSAM have disrupted or loss of 
upregulation of a subset of epithelial  and craniofacial genes. D) UCSC genome browser tracks 
showing defects (red box) in establishing open chromatin and inducing gene expression at 
LAMB3, a gene involved in craniofacial development. 
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Supplemental Figure 2.4: Heatmap of genes regulated by p63+KLF4 that have been 
strongly linked to CL/P in murine KD and KO models. A) Heatmap of genes regulated by 
p63+KLF4 that have been strongly linked to CL/P in murine KD and KO models.  
 
Supplemental Figure 2.5: p63/KLF4 peaks colocalize strongly with highly associated CL/P 
SNPs near IRF6, RHPN2 and GPATCH1. A)B) Overlay of SNPs and UCSC genome browser 
tracks highlighting in orange that p63/KLF4 peaks colocalize strongly with highly associated CL/P 
SNPs near IRF6, RHPN2 and GPATCH1, in grey binding of both proteins at promoters. 
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2.6: Supplemental Table Legends 
Supplemental Table 2.1: Genes upregulated in fibroblasts +p63 compared to control fibroblasts, 
fold change > 1.5 and FDR < 0.05 
Supplemental Table 2.2: Genes upregulated in fibroblasts +p63+KLF4 compared to control 
fibroblasts, fold change > 1.5 and FDR < 0.05 
Supplemental Table 2.3: Column 1) Genes upregulated in fibroblasts +mtDBD+KLF4 compared 
to control fibroblasts, column 2) Genes upregulated in fibroblasts +mtSAM+KLF4 compared to 
control fibroblasts, column 3) Genes no longer upregulated in fibroblasts +mtSAM+KLF4 
compared to WTp63+KLF4, column 4) Newly upregulated genes in fibroblasts +mtSAM+KLF4 
compared to WTp63+KLF4; fold change > 1.5 and FDR < 0.05 
Supplemental Table 2.4: A) Representative genes involved in isolated CL/P or CPO in murine 
KO/KD models and transcriptional regulation in control fibroblasts, fibroblasts + WTp63+KLF4 
and fibroblasts +mtSAM+KLF4 and replicates. B) List of 76 genes upregulated by p63+KLF4 
identified by genetic association database. C) List of 40 known risk loci for nsCL/P and genes 
within the TAD domains of each loci, in orange, genes upregulated by p63+KLF4. D) List of 
p63/KLF4 regulated genes and respective gene based CL/P association p-values for known 
causal genes, genes within the 40 risk loci and genes outside of the known risk loci. 
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Chapter 3: KMT2D regulates p63 target enhancers to coordinate epithelial 
homeostasis 
 
3.1: Introduction 
Proper regulation of epigenetic information through the precise control of gene enhancer 
and transcriptional networks is essential for establishing and maintaining cell fate and identity1. 
Disruption of these pathways critical for differentiation can lead to a loss of proliferative control, 
ultimately driving carcinogenesis2. In line with this, the gene encoding the chromatin modifier and 
master enhancer regulator KMT2D (MLL4) is amongst the most frequently mutated genes in 
human cancer3,4,5,6,7. There is an exceptionally high prevalence of KMT2D mutations in self-
renewing epithelial tissues ranging from the lung and esophagus to the skin and bladder, with the 
highest frequencies seen in keratinocyte cancers (cutaneous squamous cell carcinoma and basal 
cell carcinoma), the two most common forms of cancer world-wide7,8.  
Functionally, KMT2D, along with the related protein, KMT2C (MLL3), are the major 
histone methyltransferases that deposit histone H3 lysine 4 (H3K4) monomethylation (H3K4me1), 
which poises enhancers for activation and transcription factor binding9,10,11. Furthermore, in 
addition to its catalytic role in H3K4me1 deposition, KMT2D is also required for the binding of the 
histone acetyltransferase complex, CBP/p300, which acetylates H3K27 (H3K27ac) at enhancers, 
resulting in enhancer activation during cell identity gene induction and changes in cellular 
fate12,13,14. In mice, complete deletion of Kmt2d is embryonic lethal11. Tissue-specific deletion 
studies have demonstrated that KMT2D is essential for the normal development and function of 
enhancers during adipogenesis and myogenesis11, cardiac development15, and B-cell lymphocyte 
development16,17 .  
 Despite the high incidence of KMT2D mutations in the epidermis, and established roles in 
enhancer function and developmental programs in other tissues, little is understood about 
KMT2D function in normal epithelial homeostasis. Given the poor understanding yet potential 
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importance of KMT2D in development and cancer, here we explore the role of KMT2D in self-
renewing epithelia and provide the first description of KMT2D’s role at epithelial enhancers, 
including its genome-wide interactions with the transcription factor p63, master regulator of 
epithelial transcription, in coordinating key gene expression programs required for both epithelial 
cell identity and the maintenance of epithelial progenitors.  
 
3.2: Results 
3.2.1: KMT2D depletion leads to reduced proliferation and reduced expression of epithelial 
development and adhesion genes 
To study KMT2D in the epithelium, we reduced KMT2D levels in primary neonatal human 
epidermal keratinocytes (NHEKs) and in spontaneously immortalized human epidermal 
keratinocytes (HaCaTs), using short hairpin RNAs directed against KMT2D (shKMT2D) 
compared to scrambled control shRNA (shSC). RNA-seq carried out in both the NHEK and the 
HaCaT shRNA-treated keratinocytes demonstrated a significant reduction in KMT2D expression 
(Fig. 3.1A). This was confirmed by employing three distinct shKMT2D hairpins which displayed a 
consistent 2-3 fold reduction in KMT2D expression using RT-qPCR, western blotting, and 
immunofluorescence (IF) (Supplemental Figs. S3.1A-C, Fig. 3.1B). In addition, proliferative 
growth of shKMT2D keratinocytes was reduced by KMT2D loss compared to shSC keratinocytes 
(Fig. 3.1C), consistent with previous reports in other cell types18,19. To confirm that the reduced 
proliferative capacity did not reflect a simple global stress response, we examined levels of the 
senescence-associated tumor suppressor, p16/CDKN2A, and the stress and senescence-
associated transcription factor, phospho-NF-κB p65 (Ser536), and did not observe any 
differences between either shSC or shKMT2D keratinocytes (Supplemental Fig. S3.1C).  
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Figure 3.1: KMT2D loss leads to reduced keratinocyte proliferation and a broad loss of 
epithelial development and adhesion genes. (A) KMT2D mRNA expression is significantly 
reduced in both NHEK (p = 0.0036) and HaCaT (p = 0.0312) keratinocytes treated with shKMT2D 
as determined by RNA-seq. (B) shKMT2D keratinocytes display reduced levels of KMT2D, but 
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normal-appearing nuclear morphology. (C) shKMT2D keratinocytes display reduced proliferation 
in comparison to shSC keratinocytes. (D) Representative genes from shKMTD NHEKs that are 
significantly reduced in expression along with corresponding adjusted p-values. (E) Gene 
Ontology (GO) analysis of the 134 common genes lost with shKMT2D-treatment between both 
NHEK and HaCaT shKMT2D keratinocytes demonstrates that genes involved in key epithelial 
signaling pathways (RARG, VDR), epithelial cell growth and morphogenesis, polarity, and 
adhesion are enriched in amongst those genes with reduced expression. (E) shKMT2D 
keratinocytes display reduced expression of RARγ and VDR by IF (40x).  
 
Given KMT2D’s importance in transcriptional enhancer function, we examined the 
transcriptional consequences of KMT2D depletion in keratinocytes. We performed 3 biological 
replicates of RNA-seq from NHEKs treated with shKMT2D. Strikingly, we found a broad reduction 
in the expression of genes critical for epithelial development and differentiation, as well as 
adherence to the epidermal basement membrane (Fig. 3.1D). These encode proteins involved in 
epithelial development, migration, and differentiation (CYP27B1, GRHL2, PDFGB, PRKCH, 
RARG, SOX7, VDR, WNT10A)20,21,22,23,24,25, the establishment and maintenance of cell polarity 
(DLG3, DLG5, WNT7A)26 , cellular adhesion and the extracellular matrix organization (CLDN11, 
CNTN1, EMP2, IL4R, LOXL1, LOXL2, SERPINE1)27,28 , and included disease-associated 
markers of interfollicular basal epidermal stem cells essential for the function of the epidermal 
basement membrane (COL4A2, ITGA3, ITGA5, ITGB2, ITGB4, LAMA5, LAMB2)29,30  
(representative genes in Fig. 3.1D, and full list in Supplementary Table S3.1A). Similarly, we also 
performed 3 RNA-seq replicates in the HaCaT keratinocytes treated with shSC and shKMT2D. 
Overlap of all significantly reduced genes (adjusted p-value < 0.1) from both sets of keratinocytes 
demonstrated a significant overlap in the transcriptional alterations observed with shKMT2D 
treatment (134 overlapping genes, p = 3.57e-76) (Supplementary Fig. S3.1D). Gene Ontology 
(GO) analysis was carried out on the common 134 genes and showed enrichment of genes 
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related to cellular growth, extracellular matrix organization, and adhesion, including key genes 
involved in epithelial development, differentiation and morphogenesis. Notably, the vitamin D 
signaling pathway, a key cell signaling pathway involved in epithelial differentiation was also 
among the most enriched pathways (Fig. 3.1E and Supplemental Table S3.2A)23. Visualization of 
the keratinocytes by IF confirmed the loss of expression of representative genes such as RARG 
and VDR (Fig. 3.1F, G). Collectively, these results show that KMT2D reduction drives a broad 
loss of key genes typically expressed by epidermal stem and progenitor cells of the basal layer, 
as well as genes involved in proper epidermal differentiation, together suggesting a role for 
KMT2D in maintaining the hallmark gene expression program and proliferative capacity 
characteristic of epithelial progenitors.  
 
3.2.2: KMT2D is enriched genomewide at p63 target enhancers 
 To gain further insight into the function of KMT2D in the epidermis and the mechanism 
underlying keratinocyte gene expression, we mapped KMT2D binding genome-wide using 
chromatin immunoprecipitation (ChIP)-seq (full mapping information in Supplementary Table 
S3.3A). Consistent with its role in gene regulation at enhancers, a total of 1,887 KMT2D ChIP-seq 
binding sites were analyzed by DiffBind31 and HOMER suite, among which half of KMT2D peaks 
(52%) bound to intergenic regions, while introns (and likely intronic enhancers) made up the 
majority of the remaining binding sites (40%) (Fig. 3.2A). Analysis of the nearest gene to each 
peak showed that 76% of peaks were associated with protein-coding genes, while the majority of 
the others occurred near non-coding RNAs (22%) (Fig. 3.2B).  
We evaluated transcription factors binding motifs that were enriched at KMT2D binding 
regions. HOMER motif analysis of all KMT2D peaks identified p63, considered the master 
regulator of epithelial development and differentiation32, as the most highly enriched transcription 
factor motif at KMT2D binding sites (Fig. 3.2C). To examine the overlap of KMT2D peaks with 
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p63 binding sites, we intersected the nearest gene to our KMT2D peaks with consensus 
previously published p63 binding site-associated genes33,34. We verified that KMT2D peaks 
indeed overlapped directly with p63 binding sites in shSC keratinocytes using ChIP-seq. Although 
our p63 antibody identified fewer total binding sites than observed in previous reports33,34, our 
data suggested that p63 and KMT2D bound to overlapping sites across the genome, as 49% of 
p63 peaks contained a directly overlapping KMT2D peak, while another 13% of p63 peaks were 
with 100kb of a KMT2D peak. Overlapping peaks included known p63 target genes such as 
MINK1, SERINC2, and TP63 itself (Figs. 3.2E-G).  
                                                                
Figure 3.2: KMT2D co-localizes with p63 genome-wide at p63 target genes. (A) Consistent 
with its role in enhancer function, KMT2D binding is enriched in control (shSC) keratinocytes at 
intergenic and intronic regions genome-wide. (B) Over 75% of KMT2D binding sites in control 
(shSC) keratinocytes are associated with protein-coding genes, with the majority of the remaining 
binding sites associated with non-coding RNAs (ncRNAs). (C) HOMER motif analysis of KMT2D 
binding sites in shSC keratinocytes reveals a strong enrichment at p63 binding motifs. (D) 
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Intersection of consensus established p63 binding sites in keratinocytes with KMT2D binding 
sites in shSC keratinocytes demonstrates a significant overlap (p = 1.87e-142). (E) ChIP-seq for 
both KMT2D and p63 in shSC keratinocytes demonstrates that KMT2D binds at the same sites 
as p63 at known p63 target genes such as MINK1, SERINC2 (F), and TP63 itself (G). 
 
3.2.3: KMT2D and p63 interact on chromatin 
We next wanted to test for a potential direct interaction between KMT2D and p63. 
Importantly, chromatin co-immunoprecipitation experiments in NHEKs were consistent with the 
ChIP-seq data in showing that KMT2D interacts with p63 on chromatin (Supplemental Fig. 
S3.2A). In line with data showing that the ∆Np63 isoform of p63 is the predominant form of p63 
active in the epidermis, using a ∆Np63 specific antibody we determined that KMT2D interacts 
with the α, β and γ isoforms of ∆Np63, and suggesting that this interaction is not mediated by the 
C-terminal sterile alpha motif (SAM) or the transactivation (TA) domains absent in the ∆N forms of 
p63 (Supplemental Fig. S3.2B). Formaldehyde crosslinking followed by immunoprecipitation and 
mass spectrometry (IP-Massspec) further confirmed that p63 and KMT2D interact on chromatin 
(Figs. 3.3A,B). Intriguingly, these data also suggest that this interaction may in fact be mediated 
by a shared interacting partner of the more than 1000 that we identify here for the first time (Figs. 
3.3A, B, Supplemental Fig. S3.3A-C, and Supplemental Table S3.4). 
                       
Figure 3.3: KMT2D interacts with p63 on chromatin. (A) Formaldehyde crosslinking followed 
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by IP-Mass Spec shows p63 and KMT2D interact on chromatin, as immunoprecipitated KMT2D is 
able to pull down p63, and immunoprecipitated p63 is able to pull down KMT2D. We further 
observe over 1000 shared interacting partners. (B) IP-Mass Spec identifies new and known (i.e. 
RBBP5 and ASH2L) interactors of KMT2D. p63 is identified as an interactor of KMT2D in both 
crosslinked NHEKs and uncrosslinked and DNAse treated undifferentiated and differentiated 
NHEKs. 
 
3.2.4: KMT2D enrichment at p63 targets maintains expression of many key genes involved 
in epithelial homeostasis 
To test the effects of KMT2D loss, we also performed KMT2D ChIP-seq on the shKMT2D 
keratinocytes. Hierarchal clustering showed that both shSC and the shKMT2D samples clustered 
with their respective replicate dataset (Fig. 3.4A). According to DiffBind31, which employs a 
stringent peak-based approach, of the 1,887 total KMT2D peaks, 198 were identified as having at 
least a 2-fold loss of KMT2D peak size (Fig. 3.4B heatmap and black line in Fig. 3.4C metaplot). 
In addition, in order to capture more of the KMT2D changes in enrichment that we observed in 
our primary data with shKMTD-treatment, we also employed a non-peak-based approach by 
comparing the tag density (AUC) alterations in ChIP-seq enrichment with shKMT2D treatment. 
This approach identified 2,271 regions of at least a 2-fold decrease in KMT2D enrichment in 
shKMT2D keratinocytes in comparison to shSC keratinocytes (Supplementary Table S3.3A). In 
contrast, just 43 regions across the genome demonstrated a 2-fold or greater increase in KMT2D 
enrichment (Supplementary Table S3.3B). Consistent with KMT2D’s interaction with p63 and 
binding at the same sites on chromatin, motif analysis of KMT2D reduced enrichment regions in 
shKMT2D keratinocytes once again showed that p63 was the most highly enriched transcription 
factor motif (Fig. 3.4D). In contrast, regions that gained KMT2D were enriched for transcription 
factors associated with epidermal differentiation including CEBPβ and AP1-associated factors, 
BATF and Fra1 (Fig. 3.4E)35,36,37.  
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Figure 3.4: KMT2D depletion leads to a preferential loss of KMT2D at p63-target gene 
enhancers. (A) Two replicates of ChIP-seq were performed on shSC and shKMT2D 
keratinocytes, with shSC and shKMT2D clustering separately with their respective replicate 
dataset. (B) Heatmap of DiffBind-identified regions of at least 2-fold changes in enrichment 
demonstrates extensive reductions of KMT2D enrichment in shKMT2D keratinocytes. (C) 
Metaplots showing average ChIP signal near differential KMT2D binding sites across both 
replicates for shSC and shKMT2D keratinocytes. Black line indicates KMT2D-depleted regions, 
while red indicates enrichment, and gray indicates unchanged enrichment. (D) HOMER motif 
analysis of significantly lost KMT2D regions identifies p63-binding motifs as the most enriched 
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regions of KMT2D loss. (E) The few regions that gain KMT2D enrichment are enriched for 
CEBPβ motifs. (F) Intersection of all KMT2D bound region-associated genes (that lose at least 
25% enrichment averaged across both ChIP-seq replicates) and established consensus p63-
binding site-associated genes demonstrates a highly significant overlap (9.75e-127). (G) GO 
analysis of the 362 genes that are known p63-binding sites and identified here with reduced 
KMT2D enrichment demonstrates that genes associated with hemidesmosomes, cell and 
adherens junctions, focal adhesion, are highly enriched. 
 
p63 has a critical role in regulating dynamic enhancers, including super-enhancers critical 
for cell identity and cell fate specification, during epidermal development and differentiation34,38. 
Hence, we explored overlaps between established keratinocyte p63 binding sites and target 
genes33,34, and genes near KMT2D bound regions, focusing on genes that lost more than 25% 
enrichment with shKMT2D across both replicates. Here, the intersection of p63 binding sites and 
KMT2D-depleted genes was highly significant (p = 9.75e-127)(Fig. 3.4F and Supplemental Table 
S3.3C). GO analysis of these 362 “KMT2D-depleted/p63-target” genes included pathways similar 
to above: hemidesmosome assembly, cell and adherens junctions, and focal adhesion (Fig. 3.4G 
and Supplemental Table S3.2B); again including genes involved in epidermal development, 
stemness, polarity and adhesion (CNTN1, CTNNBIP1, DLG5, ITGA3, ITGB4, LAMA5, LAMC1, 
PRKCH, RARG, SERPINE1, SOX7, VDR, WNT7A, WNT10A), many of which are known to be 
p63 regulated27,33,34,39. Together, these data demonstrate that in keratinocytes KMT2D is enriched 
at p63 targets and maintains the expression of many key genes involved in epithelial 
homeostasis, including pathways involved in epidermal commitment and stratification such as the 
vitamin D and retinoid pathways, as well as numerous genes involved in regulating cell junctions 
and adhesion to the epidermal basement membrane. 
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3.2.5: KMT2D can drive the expression of p63-target genes through both catalytic histone 
methylation activity as well as catalytically independent mechanisms at enhancers. 
 KMT2D is a histone methyltransferase, thus we assayed relevant histone modifications at 
key genes, using ChIP-seq for key enhancer chromatin modifications, H3K4me1 (catalyzed by 
KMT2D), and H3K27ac (KMT2D recruits the acetyltransferase CBP/p300)12,13,14. We performed 
two replicates for each histone modification, and as expected H3K4me1 and H3K27ac clustered 
separately (Supplemental Fig. S3.4A). We identified the top 5% depleted regions (and the 
nearest associated gene) in each H3K27ac and H3K4me1 ChIP-seq replicate (Supplemental 
Table S3.5). Consistent with both the RNA-seq and KMT2D binding data, the top 5% regions of 
loss of both H3K4me1 (which KMT2D catalyzes) and H3K27ac (which KMT2D helps coordinate 
through recruitment of p300/CBP), were enriched for GO categories involved in focal adhesion, 
adherens junctions, and cell migration and proliferation (Supplemental Table S3.5). Overlap of 
the KMT2D-depleted/p63-target genes that lost gene expression by RNA-seq with the genes that 
lost enhancer histone modification enrichment identified 82 genes (Fig. 3.5A and Supplemental 
Table S3.6A). The most highly significant GO categories enriched within these 82 genes involved 
development and differentiation, consistent with both our current understanding of the roles of 
both p63 and KMT2D (Fig. 3.5B, Supplemental Table S3.2C) as well as our other results 
demonstrating the effects of KMT2D depletion on the expression of key genes involved in the 
epidermal basement membrane (COL4A2, ITGA3, ITGB4, LAMA5) and epithelial development 
and differentiation such as CTNNBIP1, DLG5, EHD1, EHD2, EMP2, PRKCH, RARG, VDR, and 
SERPINE1 (Figs. 3.5C, D and Supplemental Fig. S3.4B-G, and Supplemental Table S3.6A). In 
addition, there were 20 KMT2D-depleted/p63-target genes losing expression that did not lose 
enhancer histone modifications (at least within the top 5% loss for either H3K4me1 and H3K27ac) 
(Supplemental Table S3.6B). These genes were also involved in development and adhesion and 
included ITGA3, KRT15, IL1B, and SPARC, and TJAP1 (Supplemental Table S3.6B). These 
latter observations are consistent with recent evidence suggesting that KMT2D depletion can lead 
to extensive gene expression changes that are independent of its histone methyltransferase 
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catalytic activity40. Collectively, these results indicate that KMT2D can drive the expression of 
p63-target genes broadly involved in multiple aspects of epithelial development and 
differentiation, both through catalytic histone methylation activity as well as through other 
catalytically independent mechanisms at enhancers.  
 
Figure 3.5: KMT2D depletion provokes a loss of enhancer histone modifications and p63-
target genes. (A) Intersection of the KMT2D-depleted/p63-target genes that lose gene 
expression with those that lose enhancer histone modifications (H3K4me1 or H3K27ac) in 
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shKMT2D keratinocytes identifies 82 genes. (B) GO analysis of these 82 KMT2D-depleted/p63-
target genes that lose enhancer histone modifications shows an enrichment for genes broadly 
involved in development and differentiation. ChIP-seq tracks from representative genes that lose 
KMT2D enrichment at p63 bound regions, as well as enhancer histone modifications. Examples 
include VDR (C) and LAMA5 (D). 
 
3.2.6: KMT2D coordinates with p63 to maintain epidermal progenitor gene expression and 
proper epidermal differentiation and stratification.  
We then examined the genes that were upregulated upon shKMT2D-treatment of 
keratinocytes. GO analysis of the common genes that exhibited a significant increase (p<0.1) in 
the shKMT2D keratinocytes identified a striking enrichment of genes involved in keratinocyte 
differentiation, with the GO category “cornification” displaying an over 40-fold enrichment (Fig. 
3.6A). These genes included markers of early epidermal stratification such as KRT10 as well as 
canonical transcription factors involved in epidermal differentiation and stratification (KLF4, 
GRHL1, GRHL3, ZNF750) (Fig. 3.6B). Other genes significantly increased in shKMT2D 
keratinocytes included genes such as KRT16 and KRT17, which are typically associated with 
hyperproliferative conditions such as squamous cell carcinoma and psoriasis (Fig. 3.6B and 
Supplemental Fig. S3.5A). The combination of data showing a loss of expression of genes 
involved in the basal epidermal stem cell layer and the progenitor state, along with the 
upregulation of genes associated with keratinocyte differentiation, together suggest that in 
undifferentiated keratinocytes, KMT2D expression actively coordinates with p63 to maintain 
epidermal progenitor gene expression and thus prevent terminal differentiation.  
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Figure 3.6: KMT2D depletion provokes premature and disorganized epidermal 
stratification. (A) GO analysis of the common genes that significantly (p<0.1) gain expression in 
shKMT2D keratinocytes identifies genes involved in epithelial cornification, keratinization, 
differentiation, and development as being the most enriched. (B) Representative genes that are 
upregulated in shKMT2D keratinocytes includes genes encoding proteins that are characteristic 
of stratifying epidermis such as KRT10 and IRF6, as well as numerous members of the small 
proline rich (SPR) family of genes. Similarly upregulated are transcription factors such as KLF4, 
GRHL1, and GRHL3 associated with keratinocyte differentiation. (C) Three-dimensional (3D) 
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human organotypic skin cultures demonstrate that shKMT2D keratinocytes display altered 
differentiation dynamics, including random premature cornification, a loss of polarity, and 
disorganized stratification in comparison to shSC keratinocytes (Hematoxylin and eosin stain, 
10x). (D) IF of 3D human skin cultures demonstrates reduced levels of KMT2D throughout the 
epidermis in shKMT2D keratinocytes in comparison to shSC keratinocytes (40x). (E) Filaggrin 
and loricrin staining of 3D human skin cultures suggests both increased levels as well as 
disorganized epidermal stratification (20x).  
 
To address how these chromatin and gene expression alterations may affect human skin, 
we utilized three-dimensional human organotypic skin cultures41. These cultures allow for the 
analysis of epidermal genes and proteins during differentiation in a more human and 
architecturally relevant context than standard submerged cultures41. While shSC-treated 
keratinocytes displayed a relatively normal appearing epidermis, shKMT2D-treated keratinocytes 
appeared highly disorganized, with cells showing a loss of polarity, irregular morphologies, and 
premature cornification (Fig. 3.6D), consistent with many of the observed gene expression 
changes. IF of these sections confirmed both decreased levels of KMT2D expression (Fig. 3.6C). 
Staining for other markers associated with differentiation such as filaggrin and loricrin 
demonstrated disorganized stratification dynamics with premature and elevated expression of 
these proteins, as well as notable reduction in the expression of keratin 5, a marker of the 
epidermal progenitor cells of the basal epidermis (Figs. 3.6D-F). In order to determine whether a 
loss of p63-target gene expression was solely responsible for the premature activation of 
differentiation-associated genes, we overexpressed p63 in the shKMT2D keratinocytes. While 
significant overexpression of p63 was achieved, it was unable to reverse the gene expression 
changes observed in the KMT2D-depleted keratinocytes (Supplemental Fig. S3.5B). These 
results were not entirely surprising given KMT2D’s critical role in enhancer, transcription, and 
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transcription factor dynamics, and suggest that the effects of KMT2D on epithelial homeostasis 
and stratification dynamics are more broad than acting simply through p63.   
 
3.3: Discussion 
 An abundance of evidence has shown that p63 is critical for limb development and 
epidermal specification42,43,44, and mutations in TP63 are associated with several developmental 
disorders that display epithelial abnormalities45. Over time, p63 has come to be known as the 
master regulatory transcription factor of epithelial tissues, playing key roles at multiple levels of 
development and differentiation46,47. Excitingly, here we present evidence that KMT2D, a major 
enhancer histone methylation enzyme, and one of the most frequently mutated genes in epithelial 
cancer, is a critical regulator of p63-dependent gene expression programs and epithelial 
homeostasis. Our data indicate that KMT2D interacts with p63 on chromatin and at a broad array 
of enhancers involved in epithelial development, adhesion, and differentiation. Further, we also 
identify numerous potential new interacting proteins that may play a role in mediating the KMT2D-
p63 interaction. In turn, depletion of KMT2D in human keratinocytes leads to extensive alterations 
in normal epidermal transcriptional programs, characterized by a broad loss of expression of 
genes typically expressed in the self-renewing basal epidermal stem cell compartment such as 
basal integrin and laminin genes, as well as key regulators of proper epidermal stratification, 
including the retinoid and vitamin D signaling pathways21,23. In support of our findings, p63 has 
been shown to regulate many of the same genes we observe to be regulated by KMT2D here, 
including those involved in adhesion and vitamin D signaling39,48,49. In response to the loss of the 
expression of these genes, genes involved in keratinocyte proliferation (KRT1, KRT10, KRT6, 
KRT16, KRT17) and transcription factors that promote terminal differentiation (KLF4, GRHL1, 
GRHL3, ZNF750) are prematurely turned on.  
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As one of the largest organs in the body, the skin serves as a major barrier to the 
external environment. Similar to other epithelial surfaces, in order to maintain homeostasis, the 
epidermis undergoes regular, highly coordinated self-renewal that involves dramatic alterations in 
gene transcription and cellular architecture50. This self-renewal ability is maintained in the 
interfollicular epidermis by stem cells in the basal layer that are typically slow cycling, but with a 
high proliferative potential and self-renewing capacity, serving to ultimately supply the more 
differentiated suprabasal epidermis37,51. Our data indicates that KMT2D plays a critical role in 
epithelial homeostasis by maintaining the adhesion and proliferative capacity of the epidermal 
basement membrane through its interaction with p63 to regulate critical enhancers for genes 
involved in both maintaining the basal epidermis as well as in the proper coordination of epithelial 
stratification.  
Similar to both p63, while KMT2D may be critical for epithelial stem cell maintenance and 
gene expression, we cannot rule out that it may also play key roles later in coordinating later 
steps in terminal differentiation, as does p6346. Indeed, given its effects on genes also involved in 
the promotion of epidermal differentiation, such as the vitamin D and retinoid signaling pathways, 
it is likely KMT2D also participates in the coordination of all stages of epidermal commitment and 
differentiation. Consistent with this model, IF staining of normal skin sections for KMT2D (from 
both our lab as well as publicly available datasets) shows the presence of KMT2D in both basal 
epidermal stem cells as well as in the nuclei of cells nearing terminal differentiation 
(Supplemental Figs. S3.6A, B). This observation may offer insight into why KMT2D has been 
shown to serve both as an oncogene as well as a tumor suppressor in cancer, depending upon 
the cellular context4,16,17,53,54. Here we observe that KMT2D depletion reduces keratinocyte 
proliferation, which is consistent with reports that KMT2D deficiency slows the proliferation of both 
breast and colon cancer cell lines19,55,56 , and correlates with improved outcomes in pancreatic 
cancer53. In contrast, our data suggesting a role for KMT2D in regulating genes involved in 
vitamin D and retinoid signaling would suggest a potential tumor suppressive role23,57. Indeed, 
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deciphering these potential oncogenic versus tumor suppressive functions of KMT2D in epithelial 
cancers remains a critical question and important direction for future studies. 
3.4: Materials and methods 
3.4.1:Keratinocyte cultures 
Normal primary human epidermal keratinocytes (NHEKs) were isolated from de-identified 
discarded neonatal human foreskin obtained by Core B of the Penn Skin Biology and Diseases 
and Resource-based Center. Foreskin was incubated for 12 hours at 4C in 2.4 U/ml Dispase 
II. Sterile forceps were used to separate the underlying dermis. The epidermal sheet was 
transferred to a 60 mm tissue culture plate and incubated in 0.25% Trypsin for 10 minutes at 37C, 
then neutralized with 1 ml fetal bovine serum. Sterile forceps were used to scrape the epidermal 
sheet against the dish to dissociate cells. The suspension was passed through a 40 um strainer, 
and then centrifuged at 200g for 5 minutes. The cell pellet was re-suspended in 5 ml medium 
(see below). HaCaT keratinocytes were obtained from AddexBio. Both were cultured in a 50:50 
mix of Keratinocyte-SFM (1x) supplemented with human recombinant Epidermal Growth Factor 
1-53 and Bovine Pituitary Extract combined with Medium 154 supplemented with Human 
Keratinocyte Growth Supplement and 1% Penicillin-Streptomycin (10,000 U/mL) (all from Thermo 
Fisher Scientific). For differentiation experiments, NHEKs were cultured in media containing 1.22 
mM calcium chloride for 48 hours and then harvested. 
3.4.2: Viral transduction 
Lentiviral particles expressing scrambled control (SC) or KMT2D (MLL4)-specific shRNAs 
(D4, D5, D9) were produced using the pLKO.1-Puro viral backbone plasmid generously provided 
by the Xianxin Hua Lab at the University of Pennsylvania. Three KMT2D shRNAs were 
employed: KMT2D shRNA D4: 
 CCGGCCCACCTGAATCATCACCTTTCTCGAGAAAGGTGATGATTCAGGTG; KMT2D shRNA 
D5: CCGGCCTGAATTGAACAACAGTCTTCTCGAGAAGACTGTTGTTCAATTCA; KMT2D 
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shRNA D9: CCGGCGAATGGAAGAACAACGTGTACTCGAGTACACGTTGTTCTTCCATT. For 
the viral transductions, keratinocytes were infected with virus at 60% confluency on 10cm2 plates 
for 16 hours in the presence of polybrene. 48 hours following infections, cells underwent selection 
with puromycin to obtain completely puromycin-resistant cell populations. For the p63-
overexpression studies, NHEKs at ~60% confluency were transfected with 10µg of pcDNA3.1 
deltaNp63alpha-FLAG (Addgene #26979) and 10µl of Lipofectamine2000 diluted in 1ml of 
OptiMEM overnight (~16 hours). Cells were placed in fresh media and RNA was harvested 48 
hours following the initial transfection. 
3.4.3: Growth curve measurement 
200,000 cells were seeded on 950 mm2 surface area (one well of 6-well plate) on day 0. 
Cell number was measured every two days with Countess automated cell counter (Life 
Technologies) following standard procedures and default parameter settings, after which 200,000 
cells were plated back for the next count.  
3.4.4: Reverse-transcriptase quantitative PCR (RT-qPCR)  
RNA was extracted using RNeasy kit (Qiagen) following the manufacturer’s instructions. 
cDNA was obtained by and then was analyzed by standard qPCR methods on a 7900HT Fast-
Real-Time PCR (ABI). Primer sequences are available upon request. RT-qPCR data analysis 
was performed by first obtaining the normalized QT values (normalized to 18S ribosomal RNA). 
The average and standard deviations of biological replicates were obtained and assessed for 
significance using an unpaired t test (graphpad.com). For all experiments, 3 stars indicates 
P<0.01, 2 stars indicates P<0.05, 1 star indicates P<0.1, and NS indicates non-significance, or 
P>0.1. 
3.4.5: RNA-seq  
RNA was extracted using RNeasy kit (Qiagen catalog no. 74014) and following the 
manufacturer’s instructions. All RNA-seq libraries were prepared using the NEBNext Poly(A) 
mRNA Magnetic Isolation Module followed by NEBNext Ultra Directional RNA Library Prep Kit for 
Illumina (both from NEB). Library quality was checked by Agilent BioAnalyzer 2100 (Agilent) and 
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libraries were quantified using KAPA Library Quantification Kits (KAPA Biosystems). Libraries 
were then sequenced using a NextSeq500 platform (75bp, single-end reads) (Illumina). All RNA-
seq was aligned using RNA STAR under default settings to Homo sapiens UCSC hg19 (RefSeq 
& Gencode gene annotations). FPKM generation and differential expression analysis was 
performed using DESeq2. NHEK and HaCaT RNA-seq each consisted of three independent 
biological replicates. 
3.4.6: Immunofluorescence  
Cultured keratinocytes were fixed in 4% PFA in PBS for 30 minutes at room temperature. 
Cells were washed twice with PBS, and permeabilized with 0.5% Triton X-100 in PBS for 10 
minutes. After washing two times, cells were blocked in 10% BSA in PBS for 1 hour at room 
temperature. Cells were incubated with primary antibodies in 5% BSA in PBS supplemented with 
0.1% Tween 20 (PBST) overnight at 4°C. Antibodies are listed below. Then cells were washed 
four times with PBST, each for 10 minutes, followed by incubation with fluorophore-conjugated 
secondary antibody in 5% BSA in PBST for 1 hour at room temperature. Cells were then washed 
three times in PBST, once with PBS, and incubated with 1 µg/ml of DAPI for 5 minutes. The cells 
were then washed twice with PBS, and mounted with ProLong Gold (Invitrogen). For the 3D-
organotypic skin cultures and normal human skin sections, following exposure xylene and 
ethanol, sections were treated with target unmasking fluid to deparaffinize the tissues. Sections 
were incubated in primary antibody overnight following blocking for two hours in BlockAid 
(Thermo Fisher Scientific). Following secondary antibody incubation and washes, the sections 
were incubated with 1 µg/ml of DAPI for 5 minutes, then washed twice with PBS, and mounted 
with ProLong Gold with DAPI (Invitrogen). The slides were observed and imaged using a Nikon 
Eclipse microscope.  
3.4.7: Antibodies  
Antibodies included Anti-Histone H3 (Abcam ab1791), Anti-Histone H3 (mono methyl K4) 
(Abcam ab8895), Anti-Histone H3 (acetyl K27) (Abcam ab4729), anti-KMT2D (HPA035977) 
(Sigma-Aldrich), anti-p63-α (D2K8X) (#13109 Cell Signaling), anti-p63 (4A4) (Santa Cruz sc-
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8431), Anti-∆Np63 (Biolegend #619001), Anti-Cytokeratin 16 antibody (EP1615Y) (Abcam 
ab76416), Anti-Vitamin D Receptor antibody - ChIP Grade (Abcam ab3508), RARγ Antibody (G-
1) (Santa Cruz sc-7387). 
 
 
3.4.8: Mass spectrometry (MS) analysis and protein identification  
FLAG-tagged KMT2D protein was transfected (Life Technologies, #11668019) and 
expressed in HEK293T cells and FLAG-tagged ∆Np63α was generated by in vitro translation 
(Thermo, #88881). Subsequently, both were separately subjected to immunoprecipitation with 
FLAG antibody conjugated protein G Dynabeads (Life Technologies, #10004D). Following 
stringent washes, equal amount of lysates of undifferentiated or differentiated NHEKs were lysed 
for 1 hour at 4˚C in modified RIPA buffer containing 150 mM NaCl, 1% NP-40, 50 mM Tris-Cl, pH 
8.0, and 1% SDS, supplemented with protease inhibitors or lysate of undifferentiated crosslinked 
NHEKs (crosslinked/lysed/sonicated as above) were added. After overnight co-
immunoprecipitation, samples were thoroughly washed using a buffer containing: 20 mM Tris, pH 
8.0, 137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 1% NP-40, and protease inhibitors. Beads were 
resuspended in 50µl of 50mM Ammonium bicarbonate (NH4HCO3), samples were reduced with 
0.5µl of 1M DTT at 55˚C for 30min and then cooled down to room temperature. Samples were 
then alkylated using 2.5µl of 500mM iodacetamide for 30 min at room temperature and protected 
from light. Following this, 1.5µg of trypsin (Promega REF:V511C) was added to each sample and 
allowed to digest overnight. The next day samples were subjected to 80˚C for 10min to stop 
trypsin digestion. Tubes were placed on a magnet and peptides were transferred to a new tube. 
Beads were washed twice with 50% acetonitrile and transferred to the same tube. Finally 
samples were dried on a SpeedVac and desalted by stage tipping. After in-beads digestion, 
samples were analyzed using nano Liquid Chromatography coupled online to tandem Mass 
Spectrometry (nLC-MS/MS). Peptides were loaded onto a 75um I.D x 17cm in-house packed 
column (ReproSil-Pur C18-AQ, 3 µm) using an Easy-nLC-1000 (Thermo Scientific, San Jose, CA). 
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Peptides were eluted over 75 minutes gradient, 3-35% solvent B (A- 0.1% Formic Acid, B- 80% 
Acetonitrile, 0.1% Formic Acid) with a flow rate of 300 nl/min. The nLC was coupled to an 
Orbitrap Fusion (Thermo Scientific, San Jose, CA) operating in data-dependent mode (DDA). The 
spray voltage was set at 2.3 kV and the capillary temperature 275°C. Full MS scans were 
performed within the range 350-1200 m/z at a resolution of 120,000 (at 200 m/z). Data-dependent 
MS/MS was performed in the ion trap using top speed mode set to 3 seconds; signals with 
charge state 2+ and higher with an intensity above 10000 counts were automatically selected for 
MS/MS fragmentation performed using high-energy collision dissociation (HCD) with normalized 
collision energy of 27. MS raw files were analyzed using MaxQuant software (1.6.0.16)58 . 
Parameters for MS/MS database searching included the following: precursor mass tolerance 4.5 
ppm; product mass tolerance 0.5 Da; enzyme trypsin; missed cleavages allowed 2; static 
modifications carbamidomethyl (C); variable modifications acetyl (protein N-term) and oxidation 
(M); label-free quantification method iBAQ; database Homo sapiens (Uniprot, November 2017). 
PSMs and protein false discovery rate was filtered for < 0.01.  
3.4.9: Chromatin immunoprecipitation followed by sequencing (ChIP-seq) 
ChIP-seq was performed as previously described59. Briefly, keratinocytes cultured in 
10cm2 dishes were fixed in 1% formaldehyde for 5 minutes and fixation was quenched with 
addition of glycine to 125mM for an additional 5 minutes. Cells were harvested by scraping from 
plates, and washed twice in 1x PBS before storage at -80°C. ChIP extracts that were sonicated 9 
times for 5 minutes each round (30 seconds sonication with intermediate incubation of 30 
seconds per round) using a Bioruptor (Diagenode). All ChIPs were performed using 500 µg of 
extract and 2µg of antibody per sample. 30 µl of Protein G Dynabeads (Invitrogen) were used per 
ChIP. ChIP DNA was also used to make sequencing libraries using NEBNext Ultra DNA Library 
Prep Kit for Illumina (NEB). Library quality was checked by Agilent BioAnalyzer 2100 (Agilent) 
and libraries were quantified using KAPA Library Quantification Kits (KAPA Biosystems). Libraries 
were then sequenced using a NextSeq500 platform (75bp, single-end reads) (Illumina). Post 
sequencing, all data was demultiplexed from the raw reads using Illumina's BCL2FASTQ from 
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BaseSpace. Fastq files were aligned to Homo sapiens UCSC hg19. Tracks were visualized using 
the UCSC genome browser as described further below.  
3.4.10: ChIP-seq bioinformatics analyses 
Raw reads were mapped to the reference human genome assembly GRCh37 (hg19) 
using Bowtie2 local alignment60. The alignment result was further processed by SAMtools to 
remove low quality alignments (a minimum mapping quality of 10), duplicate reads, reads 
mapped to the mitochondria, unplaced (chrUn) and random (chr_random) contigs, and reads 
mapped to the ENCODE blacklisted genomic regions. MACS2 was used to identify ChIP-Seq 
enriched regions (or peaks)(Zhang et al. 2008), requiring peak calling FDR lower than 0.01. 
Distribution of resulting peaks in different genomic regions and motif analysis were conducted 
using HOMER suite (“annotatePeaks -size given” and “findMotifsGenome”)61 . Gene target for 
each peak was identified as gene with nearest TSS to the peak. Genome-wide tag density was 
computed using BEDTools and UCSC command line utilities to generate tracks for visualization. 
Each individual track was normalized to 1 million reads. For each ChIP sample, the 
corresponding H3 (for H3K27ac and H3K4me1) or input control (for KMT2D and p63) was 
subtracted from track using deepTools. Differential binding sites in shSC and shKMT2D 
conditions were identified by the DiffBind Bioconductor package (default parameters). Heatmaps 
were also generated by DiffBind. For KMT2D differential binding, we retrieved all sites with 2-fold 
differences for downstream analysis. Metaplot showing average ChIP signal near differential 
binding sites were generated using deepTools. Further, to include more differential binding sites 
that were not identified due to the stringency of DiffBind, a statistical test based differential 
analysis was performed. Tag density (AUC) was computed from each normalized, input-
subtracted KMT2D sample using bwtool. For each merged KMT2D peak region, we used 
Student’s T-test to examine whether its tag density is significantly different between shSC and 
scKMT2D samples. To identify the top 5% regions of histone modification loss, sequence tags for 
two replicates of H3K27ac and H3K4me1 ChIP-seq were aligned to the NCBI v37 assembly of 
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the human genome (hg19) using bowtie v1.1.1 (parameters -m 1 --best). Peaks were called for 
the two replicates using MACS2 callpeak, with matching whole histone subunit H3 ChIP-seq as a 
sonication efficiency control (parameters -s 75 -q 0.01). The peak sets for both histone PTMs 
were further filtered to use a 0.1% FDR. Peaks were then assessed for losses in the shKMT2D 
keratinocytes, and those peaks with a quantitative loss in the 95th percentile were associated to 
their nearest gene by distance to the TSS.  
 
3.4.11: Statistics 
For Venn diagrams, hypergeometric testing was performed. For RT-qPCR and the 
growth curve measurements, the standard error of the mean of three replicates is presented. 
Additional statistical methods listed in the “bioinformatics analyses” section above. 
3.4.12: Chromatin co-immunoprecipitation and western blot 
NHEKs were crosslinked in 1% formaldehyde (FisherScientific) in PBS for 5 minutes at 
room temperature. Glycine was used to quench the reaction followed by pelleting, collecting and 
lysing the cells as previously described59 . Lysed cells were sonicated with a Covaris sonicator 
(S220). The supernatant was then diluted in the final sonication buffer, split equally, and 
subjected to immunoprecipitation at 4˚C overnight with the corresponding antibodies: anti-KMT2D 
(HPA035977) (Sigma-Aldrich) and rabbit anti-IgG (Abcam ab46540). 10% of the supernatant was 
utilized for an Input control. The next day beads were washed thoroughly with RIPA buffer 
consisting of 50mM HEPES-KOH (pH 7.5), 500mM LiCl, 1mM EDTA, 1% NP-40 and 0.7% Na-
Deoxycholate. Proteins were eluted from the beads in 50mM Tris-HCL (pH 8.0), 10mM EDTA and 
1% SDS. Samples were then loaded and separated in polyacrylamide gels followed by transfer to 
a nitrocellulose membrane. Membranes were incubated in anti-p63-α antibody (Cell Signaling 
D2K8X) and imaged on a GE Amersham Imager 600. 
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3.4.13: Three-dimensional (3D) organotypic human skin cultures 
The 3D organotypic human skin cultures were performed as previously 
described(Simpson et al. 2010). Briefly, J2 3T3 fibroblasts were grown in DMEM+10% FBS. Cells 
were released from culture plates using 0.25% trypsin for 5 min at 37C, then re-suspended in 
DMEM+10% FBS and counted using a hemacytometer to determine the volume needed to obtain 
0.75-1 million fibroblasts per organotypic culture. The required volume was centrifuged in a 50 ml 
sterile conical tube at 200g for 5 minutes and the supernatant was removed. The fibroblast cell 
pellet was re-suspended in 1/10 the final required volume (2 ml per culture) of 10x Collagen Re-
suspension Buffer (1.1 g NaHCO3 plus 2.39 g HEPES in 50 ml 0.05 N NaOH) and held on ice. 
1/10th the final volume of 10x DMEM (Sigma) was then added and the cells were mixed by 
vigorous pipetting. Purified high-concentration rat tail collagen I (Corning) was added and diluted 
with sterile dH2O to a final concentration of 4 mg/ml of the final volume. 0.05 N NaOH was added 
to a pH of approximately 7. The collagen-fibroblast slurry was mixed by inverting, then 2 ml was 
pipetted into the upper chamber of a 6-well transwell insert (Corning) placed within a deep-well 6-
well tissue culture plate (Corning). The fibroblast-collagen matrices were allowed to polymerize at 
37C for 60 min. Then, the matrices were submerged in DMEM+10% FBS and placed at 37C 
overnight. The next day, NHEKs were trypsinized, re-suspended in DMEM+10% FBS and 
counted to collect 1 million cells per culture, centrifuged at 200 g for 5 min, and the supernatant 
was discarded. The NHEK pellet was re-suspended in E-medium supplemented with 5 ng/ml 
EGF (Sigma) to a volume of 2 ml per culture. The DMEM was removed from both the upper and 
lower chambers of the transwell plates containing the collagen-fibroblast matrices. 2 ml of NHEKs 
(1 million cells) were seeded atop each matrix in the upper transwell chamber and 14 ml of E-
medium with 5 ng/ml EGF was added to the bottom chamber. The cultures were placed at 37C 
overnight. The next day, the medium was aspirated from both the top and bottom chambers of 
the transwell. To place the NHEK monolayers at an air-liquid interface and induce stratification, 
10 ml E-medium (without EGF supplementation) was added only to the bottom chamber of the 
transwell and the cultures were grown at 37C for up to 12 days, feeding 10 ml E-medium every 
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other day. To generate protein lysates, the transwell apparatus was removed from the plate and 
the organotypic culture was separated from the underlying matrix using sterile forceps. The 
culture was transferred into urea sample buffer (8 M urea, 1% SDS, 10% glycerol, 60 mM Tris, 
5% beta-mercaptoethanol, pH 6.8) and dissolved by vigorous pipetting using a 25 gauge needle 
and a 1 ml syringe. Organotypic cultures were prepared for routine histology by submerging the 
culture in 10% neutral buffered formalin for 24-48 hrs. 
 
 
3.4.14: Data availability 
The relevant data sets generated during this study have beenuploaded to NCBI Gene 
Expression Omnibus and are availableunder accession numbers GSE110475, GSE110453, 
GSE110467, GSM2991421–GSM2991435, and GSM2991609–GSM2991620.  
3.4.15: Gene Ontology analyses 
All Gene Ontology (GO) analyses were performed using PANTHER at 
http://geneontology.org/page/go-enrichment-analysis. 
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3.5: Supplemental Figures 
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Supplemental Figure S3.1: (A) RT-qPCR confirms a significant loss of KMT2D mRNA 
expression with shKMT2D treatment using 3 unique shRNAs in comparison to shSC 
keratinocytes. (B) Western blotting demonstrates reduced levels of KMT2D in shKMT2D 
keratinocytes. (C) Western blotting also demonstrates no differences in the levels of the tumor 
suppressor p16/CDKN2A nor the senescence-associated transcription factor phospho-NF-κB p65 
(Ser536). (D) Intersection of the significant (p<0.1) genes with reduced expression in both 
shKMT2D NHEK and HaCaT keratinocytes in comparison to shSC keratinocytes demonstrates a 
significant overlap of 134 genes (p = 3.57e-76).  
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Supplemental Figure S3.2: (A) Formaldehyde crosslinking followed by co-immunoprecipitation 
(Co-IP) experiments show that p63 and KMT2D interact on chromatin, as immunoprecipitated 
KMT2D is able to pull down p63, while control IgG is not. (B) Using a ∆Np63 specific antibody we 
determined that KMT2D interacts with the α, β and γ isoforms of ∆Np63, suggesting the 
interaction is not mediated by the C-terminal sterile alpha motif (SAM) domain or the 
transactivation (TA) domain absent in the ∆N forms. 
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Supplemental Figure S3.3: (A) IP-Mass Spec identifies interactors of p63, e.g. STAT1. KMT2D 
is identified as an interactor of p63 in both crosslinked NHEKs and uncrosslinked and DNAse 
treated differentiated NHEKs. (B) IP-Massspec of p63 and KMT2D in undifferentiated, 
uncrosslinked and DNAse treated NHEKs reveals 256 shared interacting genes, including p63. 
(C) IP-Massspec of p63 and KMT2D in differentiated, uncrosslinked and DNAse treated NHEKs 
reveals 254 shared interacting genes, including p63. 
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Supplemental Figure S3.4: (A) Hierarchal clustering of two replicates of both H3K4me1 and 
H3K27ac demonstrates separate clustering of the two unique histone modifications. ChIP-seq 
tracks from representative genes that lose KMT2D enrichment at p63 bound regions, as well as 
enhancer histone modifications. Examples include EHD2 (B), CTNNBIP1 (C), EMP2 (D), 
SERPINE1 (E), and RARG (F). 
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Supplemental Figure S3.5: shKMT2D keratinocytes display increased levels of Krt16 staining by 
IF in comparison to shSC keratinocytes (40x).  
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Supplemental Figure S3.6: (A) IF staining of normal human epidermis with KMT2D antibodies 
demonstrates that KMT2D (red) is present both in the basal epidermis (white arrows) that is also 
keratin 14 positive, but also in the outer more differentiated layers (yellow arrows), suggesting 
that it may play a role at all levels of epithelial stratification and differentiation. (B) Publicly 
available immunohistochemistry (IHC) data (antibody HPA035977) from the Human Protein Atlas 
displays similar findings of KMT2D’s presence at all levels of the epidermis, including the basal 
epidermal layer. (C) Overexpression of p63 in shKMT2D keratinocytes does not rescue the 
premature activation of differentiation-associated genes such as KRT1 and KRT10. 
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Chapter 4: Conclusions and Future Directions 
 
 
4.1: Summary and main findings 
 
A key role of transcription factor p63 in mediating epidermal commitment, development, 
and differentiation has been extensively demonstrated through mouse models and causative 
point mutations in human disease. In mice, knockout of p63 leads to developmental and 
morphological defects in the squamous epithelia and epidermis, causing abnormal craniofacial 
development, truncated limbs, and loss of salivary glands, hair follicles, and teeth1,2. In humans, 
germline missense mutations in p63 cause ectodermal dysplastic syndromes, which are 
characterized by orofacial clefting and limb malformations3. To date, how p63 engages and 
modifies chromatin to promote normal development during these early stages is still being 
elucidated.  
Here we report a trans-differentiation model as a novel approach to determine the role of 
p63 in craniofacial development. We show that p63 can establish epithelial enhancers to regulate 
downstream genes and that this process is disrupted when p63 carries mutations derived from 
human disease. In particular, our results show a novel mechanism underlying pathogenic p63 
mutations, in which failure to open and establish enhancers leads to transcriptional dysregulation. 
We integrate our epigenomic data with GWAS datasets derived from nsCL/P patients to identify 
novel CL/P candidate genes regulated by p63. We also uncover strong enrichment of nsCL/P-
associated SNPs at enhancers established by p63, providing mechanistic insight into how these 
SNPs lead to human pathogenesis.  Further, in a follow up study, we identify histone 
methyltransferase KMT2D as a key partner of p63 at epithelial enhancers. Our data demonstrates 
for the first time a critical role for KMT2D in epithelial homeostasis by maintaining the adhesion 
and proliferative capacity of the epidermal basement membrane through its interaction with p63 to 
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regulate critical enhancers for genes involved in both maintaining the basal epidermis as well as 
in the proper coordination of epithelial stratification.  
In our first study4 using an inducible trans-differentiation model converting fibroblasts into 
keratinocyte-like cells we demonstrated the following main findings: 
1. p63 establishes enhancers to upregulate epithelial and inflammation genes: while 
previous studies had focused on the role of p63’s engagement with chromatin during 
keratinocyte differentiation5–7, de novo engagement of p63 with chromatin had not been 
extensively addressed due in part to a lack of tractable human models. 
 
2. Co-binding of p63 and KLF4 leads to robust establishment of enhancers that correspond 
remarkably well to bone fide enhancers in basal and differentiating keratinocytes: based 
on published reports8 we expanded our in vitro system to better recapitulate the 
epigenetic conditions of early development.  
 
3. Binding of p63 to chromatin is a pre-requisite for enhancer establishment: using a patient 
derived p63 mutation in the DBD we show complete loss of p63 binding to chromatin and 
loss of enhancer establishment. 
 
4. Binding of p63 to chromatin is required but not sufficient for enhancer establishment: an 
AEC patient derived substitution mutation in the SAM domain of p63 leads to a protein 
that retains binding to chromatin but shows defects in enhancer establishment. The main 
defect is in opening chromatin, pointing towards a potentially novel function of the p63 
SAM domain in recruiting chromatin remodelers for enhancer establishment. Further, our 
results contrast a recent report9 suggesting the main disease mechanism in AEC is 
aggregation of mutant p63, and posits a novel molecular link to explain disease 
phenotypes found in these patients. 
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5. We identified potential candidate causative genes for cleft lip/palate regulated by p63 at 
and outside of known risk loci: by integrating epigenomic data-sets from our trans-
differentiation model with GWAS datasets we were able to gain novel insights into 
molecular mechanisms underlying nsCL/P. In particular, we were able to prioritize 
candidate genes within half of the known risk loci and also identify over 100 new 
candidate genes and risk loci for nsCL/P. Importantly, our analysis also has the potential 
to identify the enhancers that regulate them. 
 
6. Enhancers established by p63+KLF4 are enriched for SNPs associated with nsCL/P: 
using 2 different co-localization analyses we identify enrichment of SNPs associated with 
nsCL/P only at newly established enhancers. This thus provides a novel molecular 
mechanism for how these SNPs may contribute to disease at a molecular level. 
 
Taken together, our findings in our first study address how p63 binds and remodels chromatin 
with its first encounter, identifies and prioritizes nsCL/P candidate genes and the enhancers that 
regulate them, and provides new explanations for how p63 mutations and SNPs associated with 
nsCL/P underlie disease.  
In our second study7 we wanted to ask which proteins interact with p63 on chromatin to 
establish enhancer structure. We identified methyltransferase KMT2D interacting with p63 at a 
broad array of enhancers involved in epithelial development, adhesion, and differentiation. The 
main findings in this study were: 
1. KMT2D plays a key role in maintaining the hallmark gene expression program and 
proliferative capacity of epithelial progenitors: KMT2D, one of the most frequently 
mutated genes in human cancer, has been extensively characterized. However, its 
role in epithelial cells and homeostais had not been previously explored. We show 
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depletion of KMT2D leads to reduced proliferation and reduced expression of 
epithelial development and adhesion genes, including DLG2, RARG, ITGB4 and 
LAMB2. 
 
2. KMT2D is enriched genomewide at p63 target enhancers: ChIP-seq analysis 
demonstrated that KMT2D and p63 are enriched at overlapping sites across the 
genome, with as high as 49% of p63 peaks in keratinocytes containing a directly 
overlapping KMT2D peak. Many of these included known p63 target enhancers, such 
as MINK1, SERINC2, IRF6 and TP63 itself. 
 
3. KMT2D and p63 interact on chromatin: formaldehyde crosslinking followed by 
immuno-precipitation and mass spectrometry show p63 and KMT2D interact on 
chromatin. We also find over 1000 shared binding partners which could mediate this 
interaction. 
 
4. KMT2D is enriched at p63 targets and maintains the expression of key genes 
involved in epithelial homeostasis: Knock down(KD) of KMT2D shows reduction of 
KMT2D at p63 target enhancers and reduction of gene expression of corresponding 
genes. Pathways affected include epidermal commitment and stratification, as well as 
cell junction and adhesion. 
 
5. KMT2D can drive expression of p63-target genes through both catalytic histone 
methylation activity, as well as catalytically independent mechanisms at enhancers: 
Profiling of H3K4me1 (catalyzed by KMT2D) and H3K27ac (KMT2D recruits the 
acetyltransferase CBP/p30010–12) shows KD of KMT2D correlates with loss of 
H3K4me1 and H3K27ac at p63 regulated enhancers of 82 genes involved in 
development and differentiation. In another 20 loci we observe loss of gene 
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expression with no changes in H3K4me1 and H3K27ac, consistent with recent 
evidence demonstrating histone methyltransferase independent functions of KMT2D 
in regulating gene expression13. 
 
6. KMT2D coordinates with p63 to maintain epidermal progenitor gene expression and 
proper epidermal differentiation and stratification: Investigation of genes upregulated 
upon KD of KMT2D showed a striking enrichment of genes involved in keratinocyte 
differentiation, including canonical genes, such as KLF4, GRHL1, GRHL3 and 
ZNF750. Using a three-dimensional human organotypic skin culture we observed 
keratinocytes treated with shKMT2D showed disrupted stratification dynamics, as 
well as premature cornification. Together with the above findings these results 
demonstrated a key role of KMT2D in maintaining epidermal progenitor gene 
expression and preventing terminal differentiation. 
In conclusion, we provide the first description of KMT2D’s role at epithelial enhancers, 
including its genome-wide interactions with the transcription factor p63 to coordinate key gene 
expression programs required for both epithelial cell identity and the maintenance of epithelial 
progenitors. 
For an extended discussion on both studies, please refer to the discussion section of 
chapter 2 (pages 45-49) and chapter 3 (pages 80-81). 
 
4.2: Future directions 
 
 The studies described in chapter 2 and 3 greatly increased our knowledge about p63’s 
role in epithelial enhancer establishment and revealed a potential disease mechanism in orofacial 
clefting, connecting SNPs and enhancer regulation. Further, they provided insight into possible 
binding partners of p63 at enhancers, including histone methyltranferase KMT2D; and described 
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a previously unknown role of KMT2D in maintaining epithelial homeostasis. However, many 
questions remain. In the following sections I will describe open questions and possible follow up 
experiments. 
 
 
4.2.1: Dissecting how specific SNPs may cause CL/P 
In chapter 2 we found SNPs highly associated to CL/P are enriched at newly established 
enhancers by p63 and KLF4. We further discussed in detail two loci that are prominently linked to 
CL/P but where a molecular mechanism to explain disease has yet to be found: 8q24 locus and 
MAFB locus14–17. Our colocalization analyses identified in both cases newly established 
enhancers by p63 and KLF4 colocalize with SNPS highly associated to CL/P, however how these 
SNPs cause disease remains to be shown. In particular, in these 2 cases and in many other 
examples we find several enhancers (exhibiting open chromatin and de novo H3K27ac) 
established by p63 and KLF4 and it remains unclear if all are necessary for downstream 
regulation of gene expression.  Further, in the case of the 8q24 locus and other known risk loci, 
the exact genes affected by the SNPs have not been determined. To start to answer these 
questions it would be interesting to test some of these enhancers using luciferase reporter 
systems to see if they are active in human keratinocytes and our trans-differentiation model, as 
well as during epidermal development and development of the lip and palate in murine models. 
SNPs could easily be integrated into these enhancer reporter assays to test their effect in gene 
expression. A more thorough, albeit technically challenging alternative is to use CRISPR systems 
to introduce specific SNPs either in our trans differentiation model or an epidermal differentiation 
model derived from pluripotent stem cells, to test how they affect downstream gene expression 
and differentiation. 
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A more high-throughput possibility to identify how newly established enhancers regulate 
downstream gene expression is using chromatin capture assays to study whether these newly 
established enhancers are looping to promoters. Looping to promoters could then be correlated 
with differential gene expression to filter key enhancers and corresponding SNPs to test. 
Another observation from our studies is that many nsCL/P highly associated SNPs 
cluster around established enhancers but do not seem to be found within regulatory elements 
(based on chromatin signature). Whether these SNPs are simply in linkage disequilibrium with 
disease causative SNPs or actively contribute to disease through independent mechanisms 
remains to be elucidated. The experiments proposed above would start to shed light into these 
processes and greatly expand our knowledge around cleft lip/palate pathogenesis. 
 
4.2.2: Understanding the role of lncRNAs in epidermal specification and differentiation 
 Another exciting result from our trans-differentiation experiments is that many lncRNAs 
become de novo expressed after establishment of enhancers by p63 and KLF4. In particular, in 
the 8q24 risk locus, which shows the strongest effect size across populations of Asian and 
European origin18 we observe de novo expression of lncRNA LINC00977. How and whether this 
and other lncRNAs regulate epidermal specification and differentiation, as well as more complex 
processes such as lip and palate development is not understood. A recent study harnessed the 
versatility of gene editing tools to probe how lncRNAs could confer resistance to melanoma 
treatments19. By using an enzymatically inactive Cas9 (dCas9) version coupled to an activating 
VP64 protein complex targeted to over 10000 lncRNA promoter regions they were able to screen 
which ones conferred a resistance phenotype, suggesting a role for specific lncRNAs in this 
process. To begin to understand the role of lncRNAs in epidermal specification and 
differentiation, I propose a similar screen. We could target a large amount of lncRNAs in human 
keratinocytes with either activation (dCas9-VP64) or repression (dCas9-KRAB) while in parallel 
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inducing keratinocyte differentiation using calcium supplemented media. After three days of 
differentiation, keratinocytes can be sorted using basal vs differentiation surface markers. 
Comparison of sgRNA counts can then point us towards lncRNAs crucial for keratinocyte 
differentiation. We could then confirm their function using three-dimensional skin organotyoic 
cultures as described in chapter 3 and then test their role in development using murine models. 
 
 
4.2.3: Identifying new SNPs associated to CL/P and CPO 
A remarkable finding from the GWAS data on CL/P is that the 40 identified risk loci 
explain about 25% of the cases of non-syndromic cleft lip/palate20,21. This is particularly surprising 
given the small sample sizes profiled (between 100-1000 patients per cohort). Most of the data 
has been collected from patients of Asian and European descent. In order to better understand 
genetic effects and how non-coding regions can cause orofacial clefting, it is imperative to 
increase the number of patients sequenced, as well as expanding to diverse non-European 
populations. Further, while GWAS have provided important insight into CL/P, much more remains 
unknow about cleft palate only (CPO) pathogenesis. To date, only a single risk loci has been 
confidently identified to explain CPO22. A major challenge here is the lower incidence of cases, as 
well as lack of large samples of data collected in these populations. 
 
4.2.4: Understanding discordant phenotypes in identical twins with p63 mutations 
 A key observation in patients with p63 substitution mutations is that all patients found so 
far are heterozygous for the mutation and that even patients with the same mutation show very 
different phenotypes. Given the severe phenotype observed in mice with homozygous deletion of 
Trp63 (encoding for p63 in mice)1,2 it is likely that complete loss of function of p63 in humans is 
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embryonically lethal. A recent study23 reported the first case of monozygotic twins carrying a p63 
mutation in the DBD. Interestingly, the twins exhibited discordant phenotypes, with one twin 
showing limb malformations and normal craniofacial development and the other showing normal 
limb development but CL/P23. Together with our studies and the fact that p63 acts as a tetramer, 
this suggests there is an important dose and spatiotemporal component to p63’s epithelial 
enhancer establishment during development. Previous studies looking at heterogenous 
composition of tetramers in p53 found that tetramers composed of at least three mutant p53 
proteins showed impairment of transcriptional activity24. It is possible that a similar effect is seen 
in patients carrying a substitution mutation in one of their p63 alleles. To test this hypothesis, it 
would be interesting to overexpress wildtype p63 in a cell line that does not endogenously 
express it. In parallel, mutant versions of p63 could be introduced under a doxycycline inducible 
promoter and effects on gene expression could be monitored. It would also be interesting to 
obtain keratinocytes from the monozygotic twins mentioned above and profile active enhancers to 
see if there are specific differences in enhancer structures. Given the stochastic nature of 
tetramer formation, it may be possible that defects on enhancer establishment and gene 
regulation may be lost within a population of cells. A better system would be to utilize a murine 
model in which a substitution mutation is introduced in a single allele of p63 followed by 
monitoring diverse phenotypes, more effectively recapitulating the spatiotemporal and dose 
dependent nature of p63’s enhancer establishment in development. 
 
4.2.5: Translation to treatment to prevent orofacial clefting 
 An important question is how a better understanding of p63’s role in orofacial clefting can 
be translated into therapy, especially since CL/P is one of the most common congenital 
malformations reported, second only to heart congenital malformations20. Firstly, in the case of 
patients carrying a substitution mutation in p63, patients could possibly benefit from silencing of 
the mutant allele during development. This idea is bolstered by the observation that mice with 
113	
	
homozygous deletion of p63 show severe phenotypes that are lethal shortly after birth, while 
heterozygous mice with only 1 allele of p63 deleted show no difference compared to mice with 
two copies of WT p6325. How this would be achieved in human embryo development is presently 
unclear, a therapy involving allele specific siRNA or a small molecule inhibitor that only 
recognized mutant versions of p63 are a possibility but must be thoroughly tested for safety and 
efficiency. 
 Downstream pathways affected by p63 enhancer establishment may provide less 
disruptive treatment possibilities to prevent orofacial clefting. For example, we observe p63 
establishes enhancers upstream of folic acid receptors FOLR1 and FOLR3 and that 
establishment of enhancers is followed by de novo expression of the respective genes in our 
trans-differentiation model. In mice it has been observed that KO of folbp1 (encoding for the 
homolog of FOLR1 in mice) leads to orofacial clefting26. This phenotype can be mitigated by 
supplementation of folic acid during embryo development in these mice. Similarly, it may be 
possible that defects in enhancer establishment in humans due to SNPs at enhancers of folic acid 
receptors lead to poor upregulation of these receptors and that risk of orofacial clefting might be 
mitigated through supplementation of folic acid in families that carry these SNPs. 
 
4.2.6: Molecular mechanism behind birth defects observed with thalidomide treatment 
 Thalidomide, a drug used in the 1950s to treat morning sickness in pregnant women lead 
to over 10.000 infants with birth defects in Europe27. For almost 60 years, the molecular 
mechanisms behind the resulting birth malformations were poorly understood. A recent study 
showed degradation of SALL4 as an important pathway in thalidomide induced birth defects27. 
Remarkably, the phenotypes observed in newborns, included limb and craniofacial malformations 
(e.g. CL/P) and closely mirrored the developmental phenotypes observed in patients carrying 
mutations in p63. Because of the high similarities in the phenotypes it is possible that thalidomide 
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interferes in epithelial lineage specification and enhancer establishment via p63. To test whether 
this is the case, it would be interesting to supplement cells in the fibroblast to keratinocyte-like 
trans-differentiation model with thalidomide at different doses and see if enhancer establishment 
is dysregulated. Presently, thalidomide continues to be used to treat a diverse array of diseases, 
from erythema nodosum leprosum to multiple myeloma. Treatment is correlated with significant 
adverse effects in the central nervous system, cardiovascular system and the dermis28. 
Understanding whether thalidomide interferes with enhancer establishment could provide 
important understanding of adverse effects associated with this drug. 
4.2.7: p63’s role in cancer and other disorders 
 While p63 initially garnered huge interest due to the high degree of sequence identity 
compared to p53, it was not shown to play a similar role in tumor suppression25. However, it has 
been observed that p63 is downregulated in some cancers undergoing epithelial to mesenchymal 
transition29,30, suggesting a key role of p63 in protecting and maintaining epithelial identity. 
Intriguingly, in a subset of squamous carcinomas, p63 has been shown to be overexpressed, and 
overexpression has been connected to poor outcomes31. Based on the results of our studies, it 
would be interesting to study how enhancer landscape changes with loss or overexpression of 
p63 in cancer. Particularly, in cancers where p63 is overexpressed, specific enhancers might be 
aberrantly established to modulate a gene expression program conducive to tumor growth and 
maintenance. Some evidence for this was recently reported in a subtype of pancreatic ductal 
adenocarcinoma31; however, evidence in other cancer subtypes remains to be elucidated. 
 Another interesting phenotype observed in p63 KO mice and human patients carrying 
substitution mutations of p63 is T-cell lymphopenia32,33. It has been demonstrated that p63 plays 
an important role in the development of the thymic epithelium32. Importantly, in our first study we 
observed upregulation of genes involved in immune function when p63 was overexpressed by 
itself in dermal fibroblasts. Thus, our system might provide novel insight into T-cell lymphopenia 
and other diseases involved in T-cell development and maturation. 
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4.2.8: Mass spectrometry to dissect what parts of p63 recruit chromatin modifiers and 
other proteins to establish enhancers 
 Our experiments introducing substitution mutations in p63 revealed that the SAM domain 
of p63 is crucial for promoting open chromatin during enhancer establishment in epithelial lineage 
specification. Nevertheless, it remains unclear which proteins can engage and interact with the 
SAM domain of p63 to achieve this and it is also unknown how substitution mutations disrupt this 
process. To identify novel interacting partners, it would be interesting to clone and recombinantly 
purify a WT and a mutated version of the p63 SAM domain, followed by binding to a column and 
flow through of keratinocyte cell lysate. To the best of our knowledge, such a study has not been 
conducted yet. Interacting partners could then be isolated and probed using conventional bottom-
up mass spectrometry methods, as shown in chapter 3. These could then be validated in our 
trans-differentiation model using shRNA knock downs to study their effects on chromatin 
remodeling and enhancer establishment. 
 
4.2.9: Integration of GWAS data and epigenomics in other diseases 
 Around 85% of human DNA under evolutionary constraint corresponds to non-coding 
protein-sequences34,35 a large fraction of which correspond to cis-regulatory elements. To date, 
many examples have been reported in which genetic variation at these sequences can cause 
disease36–39. At the same time, a plethora of GWAS studies have been carried out for all kinds of 
diseases, from rheumatoid arthritis to coronary heart disease and bipolar disorder. A main 
takeaway from these studies is that the vast majority of disease associated SNPs are not found 
within exons but rather at intronic and intergenic regions. While more recent studies have begun 
to combine gene expression data and expression quantitative trait loci (eQTLs) with GWAS 
data40, they have garnered limited success. Particularly in the case of development, integration of 
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trans-differentiation and in vitro differentiation strategies similar to the one we show in chapter 2 
could provide better insight into how specific SNPs may alter cis-regulatory elements to modulate 
gene expression. 
 
 
 
4.2.10: KMT2D in cancer  
 The gene encoding the histone methyltransferase KMT2D is amongst the most frequently 
mutated genes in human cancer41–45. Previous studies have reported conflicting roles for KMT2D 
either as an oncogene or as a tumor suppressor in cancer, dependent on cellular context42,46,47. 
Our results in chapter 3 demonstrated that KMT2D depletion reduces keratinocyte proliferation, 
which is consistent with reports that KMT2D deficiency slows the proliferation of both breast and 
colon cancer cell lines48,49, and correlates with improved outcomes in pancreatic cancer50. In 
contrast, our data suggesting a role for KMT2D in regulating genes involved in vitamin D and 
retinoid signaling would suggest a potential tumor suppressive role51,52. Indeed, deciphering these 
potential oncogenic versus tumor suppressive functions of KMT2D in epithelial cancers remains a 
critical question and important direction for future studies. Interestingly in pancreatic ductal 
adenocarcinoma reduced expression of KMT2D has been reported to correlate with better 
outcome50, while overexpression of p63 has been demonstrated to lead to enhancer rewiring and 
poor outcome31, pointing towards a role of KMT2D together with p63 in driving carcinogenesis in 
this type of cancer. More experiments must be conducted to understand how these proteins 
function together in the context of pancreatic cancer. 
An additional intriguing observation from our mass spectrometry studies in chapter 3 is 
that KMT2D and wild type p53 can interact directly. A previous study from our lab showed that 
mutant p53 could interact with KMT2A, an H3K4 methyltransferase in the same family of proteins 
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as KMT2D, to drive cancer growth53. Given the key role of p53 in tumor suppression, it would be 
interesting to further characterize the interaction between these two proteins in the context of 
normal tumor suppression and in cancer. 
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